WO2005123684A2 - Enantioselektive preparation of quinoline derivative - Google Patents

Enantioselektive preparation of quinoline derivative Download PDF

Info

Publication number
WO2005123684A2
WO2005123684A2 PCT/EP2005/006686 EP2005006686W WO2005123684A2 WO 2005123684 A2 WO2005123684 A2 WO 2005123684A2 EP 2005006686 W EP2005006686 W EP 2005006686W WO 2005123684 A2 WO2005123684 A2 WO 2005123684A2
Authority
WO
WIPO (PCT)
Prior art keywords
quinolin
hydroxy
formula
ethyl
substituted oxy
Prior art date
Application number
PCT/EP2005/006686
Other languages
French (fr)
Other versions
WO2005123684A3 (en
Inventor
Olivier Lohse
Caspar Vogel
Gerhard Penn
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32799952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005123684(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US11/569,140 priority Critical patent/US20090054653A1/en
Priority to KR1020067026958A priority patent/KR101179302B1/en
Priority to DK05770221.9T priority patent/DK1791820T3/en
Priority to PL05770221T priority patent/PL1791820T3/en
Priority to BRPI0512298-8A priority patent/BRPI0512298A/en
Priority to AT05770221T priority patent/ATE450512T1/en
Priority to NZ551276A priority patent/NZ551276A/en
Priority to CA2566388A priority patent/CA2566388C/en
Priority to CN2005800195899A priority patent/CN1968927B/en
Priority to MXPA06014695A priority patent/MXPA06014695A/en
Priority to AU2005254698A priority patent/AU2005254698B2/en
Priority to DE602005018076T priority patent/DE602005018076D1/en
Priority to JP2007517180A priority patent/JP5064214B2/en
Priority to EP05770221A priority patent/EP1791820B1/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of WO2005123684A2 publication Critical patent/WO2005123684A2/en
Publication of WO2005123684A3 publication Critical patent/WO2005123684A3/en
Priority to IL179600A priority patent/IL179600A/en
Priority to TNP2006000408A priority patent/TNSN06408A1/en
Priority to NO20070400A priority patent/NO339079B1/en
Priority to HK07110434.6A priority patent/HK1105121A1/en
Priority to HR20100087T priority patent/HRP20100087T1/en
Priority to US13/461,204 priority patent/US20120220775A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms

Definitions

  • the present invention provides a practical and high-yielding process for the large scale manufacture of 8-substituted oxy-5-(( J )-2-halo-l-hydroxy-ethyl)-(iH)-quinolin-2-ones with high enantiomeric purity, which are useful intermediates from which to prepare 5-[(R)-2- (5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2-one salts.
  • 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(_!H)-quinolin-2-one salts are ⁇ -selective adrenoceptor agonists with potent bronchodilator activity.
  • 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2-one maleate is especially useful for treating asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the invention provides a process for preparing 8-substituted oxy-5-((R)-2- halo-l-hydroxy-ethyl)-(2i 1 f)-quinolin-2-ones or acceptable solvates thereof comprising reacting a 5-( ⁇ -haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((.R)-2-halo-l- hydroxy-ethyl)-(2i-Z)-quinolin-2-one, said chiral agent having a formula I or II
  • M is Ru, Rh, Ir, Fe, Co or Ni
  • L is Cg-C 2 -aryl or a C ⁇ ;-C 24 -aryl-C ⁇ -C ⁇ o-aliphatic residue, in either case being optionally linked to a polymer;
  • X is hydrogen or halo
  • R 1 is a C ⁇ -C ⁇ o-aliphatic, C 3 -C ⁇ o-cycloaliphatic, C 3 -C ⁇ o-cycloaliphatic- C ⁇ -C ⁇ o-aliphatic, Cg-
  • R 2 and R 3 are phenyl, or R 2 and R 3 together with the carbon atom to which they are attached form a cyclohexane or cyclopentane ring.
  • This process provides an efficient process for preparing 8-substituted oxy-5-((R)-2-halo-l- hydroxy-ethyl)-(2H)-quinolin-2-ones, especially 8-phenylmethoxy-5-((. )-2-chloro-l- hydroxy-ethyl)-(2H)-quinolin-2-one, for large scale production with high enantiomeric purity and yield.
  • Halo or halogen denotes an element belonging to group 17 (formerly group VH) of the Periodic Table of Elements, which may be, for example, fluorine, chlorine, bromine or iodine.
  • halo or halogen is chlorine, bromine or iodine.
  • C ⁇ -C ⁇ o-Aliphatic residue or group denotes an acyclic, saturated or unsaturated, non-aromatised hydrocarbon group having up to 10 carbon atoms, for example C ⁇ -C ⁇ o-alkyl, C 2 -Oo-alkenyl or C 2 -C ⁇ o-alkynyl.
  • the G-C ⁇ 8 -aliphatic residue or group is a C ⁇ -C 4 -aliphatic residue or group, especially ethyl, propyl or butyl.
  • C 3 -C ⁇ o-Cycloaliphatic residue or group denotes a cyclic, saturated or unsaturated, non-aromatised hydrocarbon group having 3 to 10 carbon atoms, for example C 3 -C ⁇ o-cycloalkyl or C3-C10 cycloalkenyl.
  • the C 3 -C ⁇ o-cycloaliphatic residue or group is a C 3 -C 8 -cycloaliphatic residue or group, especially C 3 -C ⁇ o-cycloalkyl or C3-C10- cycloalkenyl.
  • C 3 -C ⁇ o-Cycloaliphatic-C ⁇ -C ⁇ o-aliphatic residue or group denotes a Ci-Go- aliphatic residue or group as hereinbefore defined that is substituted by a C 3 -C ⁇ o-cyclo- aliphatic residue or group as hereinbefore defined, for example C 3 -C ⁇ o-cycloalkyl-C ⁇ -G o - alkyl, C 3 -C ⁇ o cycloalkyl-C 2 -C ⁇ o-alkenyl, C 3 -C ⁇ o-cycloalkyl-C 2 -Go-alkynyl, C 3 -C ⁇ o-cyclo- alkenyl-G-Cio-alkyl, C 3 -Go-cycloalkenyl-C 2 -C ⁇ o-alkenyl, C 3 -C ⁇ o-cycloalkenyl-C -C ⁇ o-alkynyl, C 3 -C ⁇ o-
  • the C 3 -C ⁇ o-cycloaliphatic-C ⁇ -C ⁇ o-aliphatic residue or group is a C 3 - C8-cycloaliphatic-C ⁇ -C -aliphatic residue or group, especially cyclopropylmethyl.
  • C6-C 24 -Aryl residue or group denotes aryl having 6 to 24 carbon atoms.
  • the C6-C 2 4-aryl residue is preferably unsubstituted, however, it may be substituted, for example, by one or more, e.g., two or three, residues, e.g., those selected from halo, Ci-Go- alkyl, halo-G-Cio-alkyl, C2-C ⁇ 0 -alkenyl, C ⁇ -C ⁇ o-alkoxy, hydroxy, -CHO, G-Cio substituted oxy, C 2 -C ⁇ o-alkanoyl-oxy, phenyl, phenoxy, halo-substituted-phenoxy, amino, C1-C10- alkylamino, di(C ⁇ -C ⁇ o-alkyl)amino, nitro, cyano and CF 3 .
  • the C6-C 24 ⁇ aryl residue or group is a C ⁇ -C 2 o-aryl residue or group, especially phenyl, isopropylmethylbenzene (cymene), benzene, hexamethylbenzene, mesitylene, 4-chloro-4-phenoxy-phenyl, 4-phenoxy- phenyl, 5-dimethylamino-l-naphthyl, 5-diethylamino-l-naphthyl, 5-nitro-l-naphthyl, 2- nitrophenyl, 3- nitrophenyl, 4-nitrophenyl, 4-vinylphenyl, 4-biphenylyl, 9-anthracenyl, 2- hydroxyphenyl, 3- hydroxyphenyl, 4-hydroxyphenyl, tolyl, phenanthryl, dimethyl- (naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysen
  • C6-C 2 -Aryl-C ⁇ -C ⁇ o-aliphatic residue or group denotes a G-Cio-aliphatic residue or group as hereinbefore defined that is substituted by a C6-C 24 -aryl residue or. group as hereinbefore defined.
  • the Cs-C 24 -aryl-C ⁇ -C ⁇ o-aliphatic residue or group aryl- aliphatic residue is a C6-C 2 o-aryl-C ⁇ -C -aliphatic residue or group, especially phenyl-G-C - alkyl, phenyl-C 2 -C 4 -alkenyl or phenyl-C 2 -C -alkynyl.
  • Ci-Cio-Alkyl denotes straight chain or branched alkyl having 1 to 10 carbon atoms.
  • G-Qo-alkyl is C ⁇ -C 4 -alkyl.
  • C 2 -C ⁇ o-Alkenyl denotes straight chain or branched alkenyl having 2 to 10 carbon atoms.
  • C 2 -C ⁇ o-alkenyl is C 2 -C -alkenyl.
  • C 2 -C ⁇ o-AlkynyI denotes straight chain or branched alkynyl having 2 to 10 carbon atoms.
  • C 2 -C ⁇ o-alkynyl is C 2 -C -alkynyl.
  • C 3 -Go-Cycloalkyl denotes cycloalkyl having 3 to 10 ring carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, any of which can be substituted by one, two or more C ⁇ -C 4 -alkyl groups, particularly methyl groups.
  • C 3 -C ⁇ o-cycloalkyl is C 3 -Cs-cycloalkyl, especially C 3 -C6-cycloalkyl.
  • C 3 -C ⁇ o-Cycloalkenyl denotes cycloalkenyl having 3- to 10-ring carbon atoms, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl or cyclooctenyl, any of which can be substituted by one, two or more C ⁇ -C 4 -alkyl groups, particularly methyl groups.
  • C 3 -Go-cycloalkenyl is C 3 -C 8 -cycloalkenyl, especially C 3 -C6-cycloalkenyl, in particular, cyclopent-2-en-yl, cyclopent-3-en-yl, cyclohex-2-en-yl or cyclohex-3-en-yl.
  • Benzo-C 3 -C ⁇ rj-cycloalkyl denotes C 3 -C ⁇ o-cycloalkyl as hereinbefore defined attached at two adjacent carbon atoms to a benzene ring.
  • benzo-C 3 -C ⁇ o-cyclo- alkyl is benzo-C 3 -C 8 -cycloalkyl, especially, benzocyclohexyl (tetrahydronaphthyl).
  • C 3 -C ⁇ o-Cycloalkyl-C ⁇ -C ⁇ o-alkyl denotes Ci-Go-alkyl as hereinbefore defined that is substituted by C 3 -C ⁇ o-cycloalkyl as hereinbefore defined.
  • C 3 -C ⁇ o-cycloalkyl- Ci-Go-alkyl cycloalkylalkyl is C 3 -C 8 -cycloaIkyl-C ⁇ -C 4 -aIkyl.
  • C7-C 34 -Aralkyl denotes straight-chain or branched C6-C 2 4-aryl-C ⁇ -C ⁇ o-alkyl. and may be, e.g., one of the G-Cio-alkyl groups mentioned hereinbefore, particularly one of the C ⁇ -C -alkyl groups, substituted by phenyl, tolyl, xylyl or naphthyl.
  • C 7 -C 3 - aralkyl is C7-C ⁇ 4 -aralkyl, especially phenyl-C ⁇ -C 4 -alkyl, particularly benzyl or 2-phenylethyl.
  • Ci-Go-alkoxy is G-C -alkoxy.
  • 4- to 12-membered heterocyclic group denotes a monovalent heterocyclic group having 4 to 12 carbon atoms and one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur.
  • the 4- to 12-membered heterocyclic group may be, for example, a monocyclic ring with one nitrogen, oxygen or sulfur atom, such as azetidinyl, pyrryl, pyridyl, piperidyl, pyranyl, furyl, tetrahydrofuryl or thienyl, a monocyclic ring with two hetero atoms selected from nitrogen, oxygen and sulfur, such as imidazolyl, pyrimidinyl, piperazinyl, oxazolyl, isoxazolyl, thiazolyl, morpholinyl or thiomorpholinyl, or a bicyclic ring such as benzazole, indole, benzimidazole, indazole, benzothiophene, be
  • the 4- to 12-membered heterocyclic group can be an unsubstituted or substituted.
  • Preferred substituents on the heterocyclic ring include halo, cyano, hydroxy, carboxy, aminocarbonyl, nitro, C ⁇ -C ⁇ o-alkyl, hydroxy-C ⁇ -C -alkyl, G-Cio-alkoxy, C3-G0- cycloalkyl, C ⁇ -C 4 -alkylcarbonyl and phenyl-C ⁇ -C 4 -alkyl.
  • the 4- to 12-membered heterocyclic group is a 5- to 8-membered heterocyclic group, especially a monocyclic ring having one or two nitrogen or oxygen atoms such as pyranyl or 2-, 3- or 4-pyridyl, or one nitrogen atom and one oxygen atom, in the ring and optionally substituted on a ring nitrogen atom by C ⁇ -C -alkyl, hydroxy-C ⁇ -C -alkyl, C ⁇ -C 4 -alkylcarbonyl or phenyl-G-C 4 -alkyl, or a bicyclic ring such as benzo[l,3]-dioxole.
  • a monocyclic ring having one or two nitrogen or oxygen atoms such as pyranyl or 2-, 3- or 4-pyridyl, or one nitrogen atom and one oxygen atom, in the ring and optionally substituted on a ring nitrogen atom by C ⁇ -C -alkyl, hydroxy-C ⁇ -C -al
  • Halo-C ⁇ -C ⁇ o-alkyl denotes straight-chain or branched alkyl as hereinbefore defined that is substituted by one or more, e.g., one, two or three, halogen atoms as hereinbefore defined.
  • halo-G-Cio-alkyl is halo-C ⁇ -C 4 -alkyl, especially where halo is fluorine or chlorine.
  • Substituted silyl group as used herein denotes is preferably a silyl group substituted with at least one Ci-Go-alkyl group as herein defined.
  • the chiral agent has formula I or II as hereinbefore defined, wherein
  • M is ruthenium
  • L is isopropylmethylbenzene, benzene, hexamethylbenzene or mesitylene
  • X is hydrogen or halo, preferably chloro
  • R 1 is phenyl, 2- or 3- or 4-pyridyl, 4'-chloro-4-phenoxy-phenyl, 4-phenoxy-phenyl, 5- dimethylamino-1-naphthyl, 5-nitro-l-naphthyl, 2-, 3-, 4-nitrophenyl, 4-vinylphenyl, 4- biphenylyl, 9-anthracenyl, 2-, 3- or 4-hydroxyphenyl, tolyl, phenanthryl, benzo[l,3]-dioxole, dimethyl(naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysenyl, perylenyl or pyranyl; and
  • R 2 and R 3 are both phenyl.
  • the chiral agent is a ruthenium based chiral agent, especially RuCl[(iS,2S)-p-TsN-CH(C 6 H 5 )CH(C6Hj)- NH 2 ] (r -p -cymene) .
  • the invention provides a process for preparing 5-[(R)-2-(5,6-diethyl-indan- 2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2-one salts comprising:
  • R is a protecting group
  • R is a protecting group and A- is an anion
  • A" is an anion
  • the invention provides a process for preparing 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-hydroxy-(27 ⁇ )-quinolin-2-one salts comprising:
  • Step (b) reacting the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one prepared in Step (a) with a compound having the formula R-Q in the presence of a base and a solvent to form 5- acetyl- 8-substituted oxy-( JH)-quinolin-2-one, wherein R is a protecting group and Q is a leaving group;
  • R is a protecting group
  • A" is an anion
  • the present invention provides a process for preparing 8-substituted oxy-5- ((R)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-ones or acceptable solvates thereof comprising reacting a 5-( ⁇ -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one with a reducing agent in the presence of a chiral agent of formula I or II and a base to form a 8-substituted oxy-5-(( ⁇ )- 2-halo-l-hydroxy-ethyl)-(lH)-quinolin-2-one.
  • the 5-( ⁇ -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one has formula X
  • R is a protecting group
  • X is a halogen.
  • the halogen is selected from bromine, chlorine, fluorine and iodine.
  • the halogen is chlorine.
  • halogen is selected from bromine, chlorine, fluorine and iodine.
  • the halogen is chlorine.
  • the chiral agent is a compound of formula I or II as hereinbefore defined.
  • M is ruthenium, rhodium, iridium, iron, cobalt or nickel, but it is preferably ruthenium.
  • L is preferably isopropylmethylbenzene, benzene, hexamethylbenzene or mesitylene, but especially isopropylmethylbenzene.
  • L is optionally linked to a polymer. Suitable polymers include polystyrene (PS), cross-linked PS (J), polyethylene glycol (PEG) or a silica gel residue (Si).
  • Examples are NH-R 4 , wherein R 4 is C(O)(CH 2 ) n -PS or C(O)NH(CH 2 ) n -PS; and -O-Si(R s ) 2 (CH 2 )nR 6 , wherein n is 1-7, R 5 is G-C6 alkyl, e.g., ethyl, and R 6 is a polystyrene, cross-linked polystyrene, polyethylene glycol or a silica gel residue.
  • X is hydrogen or halo. It is preferably halo, especially chloro.
  • R 1 is preferably phenyl, 2- or 3- or 4-pyridyl, 4'-chloro-4-phenoxy-phenyl, 4-phenoxy-phenyl, 5-dimethylamino-l-naphthyl, 5-nitro-l-naphthyl, 2-, 3-, 4-nitrophenyl, 4-vinylphenyl, 4- biphenylyl, 9-anthracenyl, 2-, 3- or 4-hydroxyphenyl, tolyl, phenanthryl, benzo[l,3]-dioxole, dimethyl(naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysenyl, perylenyl or pyrenyl.
  • R 1 is optionally linked to a polymer.
  • Suitable polymers include polystyrene (PS), cross-linked PS (J), polyethylene glycol (PEG) or a silica gel residue (Si).
  • PS polystyrene
  • J polyethylene glycol
  • PEG polyethylene glycol
  • Si silica gel residue
  • Examples are NH-R 4 , wherein R 4 is C(O)(CH 2 ) n -PS or C(O)NH(CH 2 ) n -PS; and -O-Si(R 5 ) 2 (CH 2 ) respectfulR 6 , wherein n is 1-7, R 5 is C1-C6 alkyl, e.g., ethyl, and R e is a polystyrene, cross-linked polystyrene, polyethylene glycol or a silica gel residue.
  • R 2 and R 3 are preferably both phenyl.
  • the chiral agent of formula I reacts with a base, such as potassium hydroxide or triethylamine, in a solvent such as CH 2 C1 2 , methanol, dimethylformamide, or dimethylacetamide or a mixture of methanol and dimethylformamide or a mixture of methanol and dimethylacetamide, and upon elimination of a hydrogen halide forms a compound of formula XHI
  • a base such as potassium hydroxide or triethylamine
  • the process of the present invention is carried out by adding a chiral agent of formula I as hereinbefore defined where X is halo to the 5-( ⁇ -haloacetyl)-8-substituted oxy- (2H)-quinolin-2-one and the reducing agent in the presence of a base such as potassium hydroxide or triethylamine in a solvent such as a mixture of methanol and dimethylformamide or a mixture of methanol and dimethylacetamide.
  • the base converts the chiral agent of formula I where X is halo to the compound of formula XHI which, itself, reacts with the reducing agent to form the chiral agent of formula I where X is hydrogen.
  • the compound of formula I where X is halo is formed in situ by adding a metal- halide dimer such as[RuCl 2 (p-cymene)] 2 and a chiral ligand such as (lS,2S)-(+)-N-p-tosyl-l,2- diphenylethylendiamine separately.
  • a metal- halide dimer such as[RuCl 2 (p-cymene)] 2
  • a chiral ligand such as (lS,2S)-(+)-N-p-tosyl-l,2- diphenylethylendiamine separately.
  • the process of the present invention may also be carried out by adding a chiral agent of formula II to the 5-( ⁇ -haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one and the reducing agent in the presence of a base.
  • Chiral agents of formula II include those that are described in Puentener et al Tetrahedron Letters, 1996, Vol 37, no.45 pages 8165-8168, the contents of which is also incorporated herein by reference.
  • the chiral agent of formula II reacts with a base, such as potassium hydroxide or triethylamine, in a solvent such as CH 2 C1 2 , methanol, dimethylformamide or dimethylacetamide or a mixture of methanol and dimethylformamide or a mixture of methanol and dimethylacetamide, and upon elimination of a hydrogen halide forms a compound of formula XV
  • the process of the present invention may be carried out by adding a pre-prepared chiral agent of formula LI to the 5-( ⁇ -haloacetyl)-8-substituted oxy-( H)-quinolin-2-one and the reducing agent in the presence of a base.
  • a chiral agent of formula II where X is halo is added to the 5-( -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one and the reducing agent in the presence of a base and a solution of potassium hydroxide in a solvent.
  • the base converts the chiral agent of formula II where X is halo to the compound of formula XV which, itself, reacts with the reducing agent to form the chiral agent of formula I where X is hydrogen.
  • the compound of formula LT where X is halo is formed in situ by adding a metal-halide dimer and a chiral ligand separately.
  • the chiral agent is preferably a pre-prepared compound of formula I, especially a compound of formula XVI
  • the chiral agent is RuCl[(iS,2S)-p-TsN- CH(C 6 H5)CH(C 6 H5)-NH 2 ]( ⁇ 6 -p-cymene).
  • the chiral agent is a compound of formula I where X is halo that is formed in situ by adding the metal-halide dimer and the chiral ligand separately.
  • RuCl[(2S,25)-p-TsN-CH(C 6 H5)CH(C 6 H5)-NH 2 ]( ⁇ 6 - ⁇ -cymene) can be formed by reacting the RuCl 2 dimer, [Ru( ⁇ ⁇ -p-cymene)Cl 2 ] 2 , together with the chiral ligand, 5,S-TsDPEN ((lS,2S)-p- TsNH-CH(C 6 Hj)CH(C 6 H 5 )-NH 2 ), in situ to give RuCl[(2S,2S)-p-TsN-CH(C 6 H 5 )CH(C 6 H5)- NH 2 ]( ⁇ 6 -p-cymene), which has formula XVII
  • Suitable reducing agents include formic acid, primary alcohols and secondary alcohols.
  • Preferred reducing agents include formic acid, 2-propanol and 3-pentanol.
  • the reducing agent is preferably 2- propanol, 3-pentanol or formic acid. More preferably, the formic acid is used in the presence of an amine, most preferably a tertiary amine such as triethylamine, tributyl amine, 2,2,6,6- tetramethylpiperidine, 1,2,2,6,6-pentamethylpiperidine and N,N-diisopropylethylamine.
  • the reducing agent may also be used as a solvent, especially 2-propanol and most preferably formic acid.
  • the amount of chiral agent is preferably between about 0.1 to about 10 mole %, especially between about 0.8 and 1 mole %, referring to the compound of formula X.
  • the reaction is carried out in the presence of a base.
  • the temperature used is preferably from about -10 °C to about 80 °C, but especially from about 0 °C to about 50 °C.
  • the base is preferably a tertiary amine, for example triethylamine.
  • Triethylamine is preferably used in molar excess to formic acid as this significantly accelerates this reaction. This allows the reaction to be performed at a lower temperature, for example from about 25 °C to about 50 °C, but preferably about 30 °C. This also provides for better enantioselectivities i.e. more of the R isomer of compound of formula X is produced and less of the S isomer of that compound is produced.
  • the molar ratio of triethylamine to formic acid is from 1:1 to 2:5, but especially about 1:2.
  • the base is preferably potassium hydroxide or sodium hydroxide.
  • a solvent is preferably used.
  • the solvent is preferably an alkyl acetate, e.g. a Ci-C ⁇ -alkyl acetate such as ethyl acetate, isopropyl acetate or butyl acetate, a lower alkyl alcohol, e.g.
  • Ci-Cg-alkyl alcohol such as methanol, ethanol, propanol, isopropanol, butanol or pentanol; an aliphatic C ⁇ -C ⁇ 2 -hydro-carbon such as isooctane, heptane; dimethylformamide; dimethylacetamide; an aromatic hydrocarbon such as toluene or benzene; acetonitrile; a heterocycle such as tetrahydrofuran; a dialkyl ether such diisopropyl ether, 2-methoxyethyl ether or diethylene ether; an aqueous solvent such as water; an ionic liquid; or a chlorinated solvent such as methylenechloride.
  • a Ci-Cg-alkyl alcohol such as methanol, ethanol, propanol, isopropanol, butanol or pentanol
  • an aliphatic C ⁇ -C ⁇ 2 -hydro-carbon such as
  • a combination of solvents may also be used.
  • the solvent is preferably methanol, methylene- chloride, dimethylformamide or dimethylacetamide.
  • a combination of methanol and dimethylformamide or a combination of methanol and dimethylacetamide is especially preferred, for example using 90 volumes of methanol with 10 volumes dimethylformamide/ dimethylacetamide.
  • the 5-( ⁇ -haloacetyl)-8 -substituted oxy-(2H)-quinolin-2-one is reacted with formic acid in the presence of a chiral ruthenium agent and a tertiary amine to form the 8-substituted oxy-5-((. )-2-halo-l-hydroxy-ethyl)-(IH)-quinolin-2-one.
  • the 8-substituted oxy-5-(( J R)-2-halo-l- hydroxy-ethyl)-(:.H)-quinolin-2-one of formula XI is preferably 8-phenyl-methoxy-5-((jR)-2- chloro-l-hydroxy-ethyl)-(ifJ)-quinolin-2-one.
  • the 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(_?H)-quinolin-2-one product is optionally purified by any of the various techniques known to the art, for example by crystallization, and optionally in the presence of charcoal.
  • the 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2- ones that are prepared from 5-( ⁇ -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-ones in accordance with the first aspect of the present invention may be used to prepare 5-[(R)-2- (5,6-diethyl-indan-2-ylamino)- 1 -hydroxy-ethyl] - 8 -hydroxy-( 1 H)-quinolin-2-one salts.
  • the second aspect of the present invention involves reacting a 5-( ⁇ -haloacetyl)-8-substituted oxy- (2H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form an 8-substituted oxy-5-((. )-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one (step i), and its subsequent conversion to a 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8- hydroxy-(2H)-quinolin-2-one salt (steps ii through vii).
  • Step (i) is carried out as described above in connection with the first aspect of the present invention.
  • step (ii) the 8-substituted oxy-5-(( J R)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one formed in step (i) is converted to an 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one.
  • the 5-( ⁇ -haloacetyl)-8-substituted ox ⁇ -(lH)- quinolin-2-one is reacted with the reducing agent in the presence of the chiral agent and a base to form the 8-substituted oxy-5-(il)-oxiranyl-(2H)-quinolin-2-one in a single step i.e. steps (i) and (ii) are combined.
  • the base is preferably potassium t-butoxide, potassium hydroxide or potassium isopropoxide.
  • the chiral agent is prepared in situ, for example by adding [Ru( ⁇ 6 -p- cymene)Cl 2 ] 2 together with a chiral ligand, such as S,S-TsDPEN ⁇ (lS,2S)-p-TsNH- CH(C 6 H5)CH(C 6 H 5 )-NH 2 ) to give RuCl[(25,2S)-p-TsN-CH(C 6 H5)CH(C 6 H 5 )-NH 2 ]( ⁇ 6 -p- cymene), which is converted upon addition of a base such as potassium hydroxide or triethylamine, to give RuH[(25,2S)-p-TsN-CH(C 6 H5)CH(C 6 Hj)-NH 2 ]( ⁇ 6 -p-cymene).
  • a chiral ligand such as S,S-TsDPEN ⁇ (lS,2S)-p-TsNH- CH(C 6 H
  • the base used in step (ii) is preferably ethoxide, sodium hydroxide, potassium phosphate, potassium carbonate, potassium hydrogencarbonate or caesium carbonate, but especially potassium carbonate.
  • a combination of bases may also be used.
  • the solvent used in Step (ii) is preferably an alkyl acetate, e.g. a Ci-C ⁇ -alkyl acetate such as ethyl acetate, isopropyl acetate or butyl acetate; a lower alkyl alcohol, e.g.
  • Ci-Cg-alkyl alcohol such as methanol, ethanol, propanol, isopropanol, butanol or pentanol; an aliphatic C ⁇ -C ⁇ 2 -hydrocarbon such as isooctane, heptane; dimethylformamide; an aromatic hydrocarbon such as toluene or benzene; a dialkyl ketone such as acetone, ethyl methylketone (2- butanone) or methyl isobutyl ketone; acetonitrile; a heterocycle such as tetrahydrofuran; a dialkyl ether such diisopropyl ether, 2-methoxyethyl ether or diethylene ether; an aqueous solvent such as water; an ionic liquid; or a chlorinated solvent such as methylenechloride.
  • a combination of solvents may also be used.
  • a preferred solvent for use in Step (ii) is a combination of
  • the temperature used in Step (ii) is preferably from about 10 °C to about 160 °C. More preferably, the temperature is from about 30 °C to about 90 °C, but especially from about 50 °C to about 80 °C.
  • the 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one is preferably 8-phenlymethoxy-5- (.R)-oxiranyl-(2H)-quinolin-2-one.
  • the 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one product is optionally purified by any of the various techniques known to the art, for example by crystallization. Crystallization from toluene or acetone is especially preferred, and is optionally conducted in the presence of charcoal.
  • R is a protecting group
  • Preferred protecting groups are phenol protecting groups which are known to those skilled in the art. More preferably, the protecting group is selected from the group consisting of alkyl, aryl, alkoxy, alkenyl, cycloalkyl, benzocycloalkyl, cycloalkylalkyl, aralkyl, heterocyclic, heteroaralkyl, haloalkyl, and a substituted silyl group. Most preferably, the protecting group is benzyl or t-butyldimethylsilyl. Preferably, Step (iii) is conducted in the presence of a solvent.
  • Preferred solvents include: alcohols, e.g., Ci-salkyl alcohols, such as methanol, ethanol, propanol, butanol, and pentanol; aliphatic C ⁇ - ⁇ hydrocarbons, e.g., isooctane, heptane; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydro-furan; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; dimethyl sulfoxide; tetrahydrothiophene 1,1-dioxide, also known as tetramethylene sulfone or as tetramethylene sulfolane; dialkyl carbonate, e.g., dimethyl carbonate and diethyl carbonate; a
  • the temperature used in Step (iii) is preferably from about 10 °C to about 160 °C. More preferably, the temperature is from about 30 °C to about 120 °C; and most preferably from about 90 °C to about 120 °C.
  • Step (iii) is conducted with a molar excess of the 2-amino-(5-6-diethyl)-indan with respect to the 8-substituted oxy-5-(R)-oxiranyl-(lH)-quinolin-2-one.
  • a molar excess of the 2-amino-(5-6-diethyl)-indan with respect to the 8-substituted oxy-5-(R)-oxiranyl-(lH)-quinolin-2-one.
  • 1.05 mole equivalent to 3 mole equivalents of 2-amino-(5-6-diethyl)-indan is used with respect to 8- substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one.
  • 1.1 mole equivalents to 1.5 mole equivalents of 2-amino-(5-6-diethyl)-indan is used with respect to 8-substituted oxy- 5-(R)-oxiranyl-(2H)-quinolin-2-one.
  • the 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one is preferably 8-phenylmethoxy-5- (R)-oxiranyl-(lH)-quinolin-2-one.
  • the 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]- 8 -substituted oxy-(2H)-quinolin-2-one is preferably 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-phenylmethoxy-( 1 H)-quinolin-2-one.
  • Step (iv) the reaction mixture prepared in Step (iii) is treated with an acid in the presence of a solvent to form a corresponding salt.
  • Preferred solvents for use in Step (iv) include: alcohols, e.g. Ci-Gs-alkyl alcohols, such as methanol, ethanol, propanol, butanol, and pentanol; aliphatic Cg-Cn-hydrocarbons, e.g., isooctane, heptane; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; dimethyl sulfoxide; tetrahydrothiophene 1,1-dioxide, also known as tetramethylene sulfone or as tetramethylene sulfolane; dialkyl carbonate, e.g., dimethyl carbonate
  • the temperature used in Step (iv) is preferably from about -10 °C to about 160 °C. More preferably, the temperature is from about 0 °C to about 120 °C; and most preferably from about 0 °C to about 75 °C.
  • the anion corresponds to the acid used in Step (iv).
  • the acid used in Step (iv) is preferably a carboxylic acid, such as benzoic acid, maleic acid, succinic acid, fumaric acid, or tartaric acid; or a mineral acid, such as hydrochloric acid. Most preferably, the acid used in Step (iv) is benzoic acid.
  • the salt having Formula VII is preferably a benzoate salt having formula XIX
  • R is a protecting group
  • benzoate salt of formula XIX is a benzoate salt having formula XX
  • Step (vi) the protecting group on the salt having formula VII is removed in the presence of a solvent to form a salt having formula VTJI
  • A- is an anion
  • the salt having formula VIII is preferably a benzoate salt having formula XXI
  • a preferred method of removing the benzyl group on the salt having formula VII is by treating the salt with hydrogen in the presence of a catalyst.
  • Preferred catalysts include palladium, palladium hydroxide, palladium on activated carbon, palladium on alumina, palladium on carbon powder, platinum, platinum on activated carbon and RaneyTM nickel. A combination of catalysts may also be used. Most preferably, the catalyst is palladium on activated carbon.
  • a preferred method of removing the t-butyldimethylsilyl group on the salt having formula VII is by treating the salt with t-butylammonium fluoride or potassium fluoride.
  • the solvent used in Step (vi) is preferably selected from an alkyl acetate, e.g., C ⁇ -C6-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; lower alkyl alkylamines, e.g., C ⁇ -C6-alkylamines; alcohols, e.g., G-Cg-alkyl alcohols, such as methanol, ethanol, propanol, butanol and pentanol; aliphatic Cg-C ⁇ 2 -hydrocarbons, e.g., isooctane, heptane, dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2-meth
  • the temperature used in Step (vi) is preferably from about 0 °C to about 70 °C. More preferably, the temperature is from about 10 °C to about 50 °C; and most preferably from about 10 °C to about 30 °C.
  • the salt having formula VHI is preferably 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl] -8 -hydr oxy- ( 1 H) -quinolin-2-one benzoate.
  • Step (vii) the salt having formula VTH is treated with an acid in the presence of a solvent to form a salt having Formula IX
  • X is an anion.
  • the anion corresponds to the acid used in Step (vii).
  • the acid used in Step (vii) is preferably a carboxylic acid, such as benzoic acid, maleic acid, succinic acid, fumaric acid, or tartaric acid. Most preferably, the acid used in Step (vii) is maleic acid.
  • the salt having formula IX is preferably 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]-8-hydroxy-(2i c Z)-quinolin-2-one maleate having formula XXII
  • the solvent used in Step (vii) is preferably selected from an alkyl acetate, e.g., Ci-Cg-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; alcohols, e.g. Ci-C ⁇ -alkyl alcohols, such as methanol, ethanol, propanol, isopropanol, butanol and pentanol; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; dialkyl ketones, e.g.
  • an alkyl acetate e.g., Ci-Cg-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate
  • alcohols e.g. Ci-C ⁇ -alkyl alcohols, such as methanol, ethanol, propanol, isopropanol, but
  • acetone and methyl isobutyl ketone acetonitrile
  • heterocycles such as tetrahydrofuran
  • dialkyl ethers e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether
  • an acid such as acetic acid and propionic acid
  • aqueous solvents such as water
  • ionic liquids ionic liquids
  • chlorinated solvents such as methylenechloride.
  • a combination of solvents may also be used. More preferably, the solvent is ethanol.
  • the temperature used in Step (vii) is preferably from about 0 °C to about 70 °C. More preferably, the temperature is from about 10 °C to about 60 °C; and most preferably from about 20 °C to about 50 °C.
  • 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy- (2H)-quinolinone-2-one salts can be prepared from 8-hydroxy-(2H)-quinolin-2-one or 8- acetoxy-(2H)-quinolin-2-one.
  • the third aspect of the present invention involves the preparation of 5-( ⁇ -haloacetyl)-8-substituted oxy-(lH)-quinolin-2-ones (steps a through c), their reaction with a reducing agent in the presence of a chiral agent to form 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-( ⁇ H)-quinolin-2-ones (step d), and their subsequent conversion to 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)- quinolinone-2-one salts (steps e through j).
  • step (a) 8-hydroxy-(lH)-quinolin-2-one or 8-acetoxy-(2H)-quinolin-2-one is converted to form 5-acetyl-8-hydroxy-(j( J ff)-quinolin-2-one.
  • step (a)(i) step (a)(ii) and step (a)(iii).
  • step (a) 8-hydroxy-(2H)-quinolin-2-one is reacted with an acylating agent and a Lewis acid to form 5-acetyl-8-hydroxy-(j[H)-quinolin-2-one.
  • step (a) 8-hydroxy-(2H)-quinolin-2-one is reacted with an acylating agent to form 8- acetoxy-(2H)-quinolin-2-one, which is then treated in situ with a Lewis acid to form 5-acetyl- 8-hydroxy-(21J)-quinolin-2-one.
  • step (a)(iii) 8-acetoxy-(lH)-quinolin-2-one is reacted with a Lewis acid to form 5-acetyl-8- hydroxy-(lH)-quinolin-2-one.
  • the 5-acetyl-8-hydroxy-(2ff)-quinolin-2-one has formula XXIV
  • the acylating agent when used, is preferably acetic anhydride or acetyl chloride.
  • the acylating agent is preferably present in an amount of from about 1 molar equivalents to about 1.5 molar equivalents, more preferably about 1.05 molar equivalents, based on the molar equivalents of 8-hydroxy-(2H)-quinolin-2-one.
  • the Lewis acid is preferably selected from boron trifluoride (BF 3 ), aluminium chloride (A1C1 3 ), and titanium tetrachloride (TiCl 4 ). More preferably, the Lewis acid is aluminium chloride. A combination of Lewis acids may also be used.
  • the Lewis acid is present in an amount of greater than 2 molar equivalents, based on the molar equivalents of 8-hydroxy-(2H)-quinolin-2-one or molar equivalents of 8-acetoxy-(2H)- quinolin-2-one. Preferably, the Lewis acid is present in an amount of about 3 molar equivalents to about 5 molar equivalents, more preferably from about 3.2 molar equivalents to about 4 molar equivalents.
  • Step (a) is conducted in the presence of a solvent.
  • Step (a) is conducted in the absence of a solvent and in the presence of an ionic compound.
  • the ionic compound is an ionic liquid or an alkaline halide.
  • a solvent is used in Step (a).
  • the solvent is preferably a solvent compatible with Friedel-Craft conditions.
  • solvents are well-known to those skilled in the art and include chlorobenzene, o-dichlorobenzene, 1,2-ethylene dichloride, aliphatic Cg.C ⁇ 2 hydrocarbons, e.g., isooctane, heptane and combinations thereof. A combination of solvents may also be used.
  • a preferred solvent for use in Step (a) is o-dichlorobenzene.
  • Step (a) may be conducted in the absence of a solvent and in the presence of an ionic compound selected from an alkaline halide and an ionic liquid.
  • the alkaline halide is preferably selected from sodium chloride, sodium bromide, lithium chloride and lithium bromide. More preferably, the alkaline halide is sodium chloride. A combination of alkaline halides may also be used.
  • Ionic liquids are characterized by a positively-charged cation and a negatively-charged anion. Generally, any molten salt or mixture of molten salts is considered an ionic liquid. Ionic liquids typically have essentially no vapour pressure, good heat transfer characteristics, are stable over a wide temperature range and are capable of dissolving a wide range of material in high concentrations. As used herein, "essentially no vapour pressure" means that the ionic liquid exhibits a vapour pressure of less than about 1 mm Hg at 25 °C, preferably less than about 0.1 mm/Hg at 25 °C.
  • the preferred ionic liquids are liquid at relatively low temperatures.
  • the ionic liquid has a melting point of less than 250 °C, more preferably less than 100 °C.
  • the ionic liquid has a melting point of less than 30 °C and is a liquid at room temperature.
  • the ionic liquid has a viscosity of less than 500 centipoise (cP), more preferably, less than 300 cP, and most preferably less than 100 cP, as determined at 25 °C.
  • the cation present in the ionic liquid can be a single species or a plurality of different species. Both of these embodiments are intended to be embraced, unless otherwise specified, by the use of the singular expression "cation".
  • the cations of the ionic liquid include organic and inorganic cations. Examples of cations include quaternary nitrogen-containing cations, phosphonium cations and sulfonium cations.
  • the quaternary nitrogen-containing cations are not particularly limited and embrace cyclic, aliphatic and aromatic quaternary nitrogen-containing cations.
  • the quaternary nitrogen-containing cation is an ⁇ -alkyl pyridinium, a dialkyl imidazolium or an alkyl- ammonium of the formula RVx NHx, wherein x is 0-3 and each R' is independently an alkyl group having 1-18 carbon atoms. It is believed that unsymmetrical cations can provide for lower melting temperatures.
  • the phosphonium cations are not particularly limited and embrace cyclic, aliphatic and aromatic phosphonium cations.
  • the phosphonium cations include those of the formula R" 4 -x PHx, wherein x is 0-3, and each R" is an alkyl or aryl group, such as an alkyl group having 1-18 carbon atoms or a phenyl group.
  • the sulfonium cations are not particularly limited and embrace cyclic, aliphatic and aromatic sulfonium cations.
  • the sulfonium cations include those of the formula R'" 3- ⁇ SHx, wherein x is 0-2 and each R'" is an alkyl or aryl group, such as an alkyl group having 1-18 carbon atoms or a phenyl group.
  • Preferred cations include 1-hexylpyridinium, ammonium, imidazolium, l-ethyl-3-methylimidazolium, l-butyl-3-methylimidazolium, phosphonium and -butylpyridinium.
  • the anion used in the ionic liquid is not particularly limited and includes organic and inorganic anions.
  • the anion is derived from an acid, especially a Lewis acid.
  • the anions are typically metal halides as described in more detail below, boron or phosphorus fluorides, alkylsulfonates including fluorinated alkyl sulfonates, such as nonafluorobutane- sulfonate; and carboxylic acid anions, such as trifluoroacetate and heptafluorobutanoate.
  • the anion is preferably Cb, Br, NO 2 ", NO 3 ", AlCLc, BF 4 ⁇ , PF ⁇ r, CF 3 COO-, CF 3 SO 3 -, (CF 3 SO 2 ) 2 N-, OAc-, CuClr, GaBr 4 ⁇ , GaCl 4 - and SbFg".
  • ionic liquids include, but are not limited to, imidazolium salts, pyridium salts, ammonium salts, phosphonium salts and sulphonium salts.
  • Preferred imidazolium salts have formula XXV
  • R a and R b are, independently, selected from the group consisting of a C ⁇ -C ⁇ _- aliphatic group and a C -C ⁇ 8 -aromatic group; and A- is an anion.
  • Preferred ammonium salts have formula XXVI
  • R c , R d , R e and R f are, independently, selected from the group consisting of a C ⁇ -C ⁇ 8 - aliphatic group and a C 4 -Ci 8 -aromatic group; and A- is an anion.
  • R c , R d , R e and R f are, independently, selected from the group consisting of ethyl, propyl and butyl.
  • Preferred phosphonium salts have formula XXVII (XXVII) wherein Re, R h , R' and Ri are, independently, selected from the group consisting of a Ci-Ci ⁇ - aliphatic group and a C -C ⁇ 8 -aromatic group; and A- is an anion.
  • R ⁇ , R h , R 1 and Ri are, independently, selected from the group consisting of ethyl and butyl.
  • Preferred pyridinium salts have formula XXVEI
  • R k is selected from the group consisting of a C ⁇ -C ⁇ 8 -aliphatic group and a C -C ⁇ 8 - aromatic group; and A ⁇ is an anion.
  • R k is ethyl or butyl.
  • ionic liquids include, but are not limited to, l-butyl-3-methylimidazol- ium hexafluorophosphate, l-hexyl-3-methylimidazolium hexafluorophosphate, l-octy-3- methylimidazolium hexafluorophosphate, l-decyl-3-methylimidazolium hexafluorophosphate, l-dodecyl-3-methylimidazolium hexafluorophosphate, l-ethyl-3-methylimidazol- ium &ts((trifluoromethyl)sulphonyl)-imidate, l-hexyl-3-methylimidazolium fots((trifluoro- methyl)sulphonyl)amide, 1-hexylpyridinium tetrafluoroborate, 1-octylpyridinium tetra- fluo
  • Preferred ionic liquids are l-ethyl-3-methyl-imidazolium trifluoroacetate, l-butyl-3-methyl- imidazolium trifluoroacetate, l-ethyl-3-methyl-imidazolium trifluoroacetate, l-butyl-3- methyl-imidazolium hexafluorophosphate, l-octyl-3-methyl-imidazolium hexafluorophosphate, l-hexyl-3-methy-imidazolium hexafluorophosphate, l-butyl-3-methyl- imidazolium hexafluorophosphate, l-butyl-3-methyl-imidazolium tetrafluoroborate, 1-ethyl- 3-methyl-imidazolium tetrafluoroborate, l-octyl-3-methyl-imidazolium bromide, l-e
  • the ionic liquid is selected from l-ethyl-3-methyl-imidazolium trifluorosulfonate, l-butyl-3-methylimidazolium chloride, l-octyl-3-methyl-imidazolium hexafluorophosphate and l-hexyl-3-methyl-imidazolium hexafluorophosphate.
  • a combination of ionic liquids may also be used.
  • the weight ratio of Lewis acid to ionic compound is from about 10 to about 0.1, respectively. More preferably, the ratio of Lewis acid to ionic compound is from about 3 to about 1, respectively.
  • the temperature used in Step (a) is preferably from about 0 °C to about 160 °C. More preferably, the temperature is from about 10 °C to about 120 °C; and most preferably from about 15 °C to about 110 °C.
  • the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one product prepared in Step (a) may also be present with 7-acetyl-8-hydroxy-(2H)-quinolin-2-one having formula XXIX
  • 7-Acetyl-8-hydroxy-(lH)-quinolin-2-one is surprisingly much more soluble than 5-acetyl-8- hydroxy-( ⁇ H)-quinolin-2-one.
  • the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one may be recovered from the reaction mixture and purified by any of the various techniques known to the art, such as by crystallization or forming a slurry in a solvent.
  • a preferred solvent for forming a slurry is acetic acid.
  • Step (b) the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one that is prepared in Step (a) is reacted with a compound having the Formula R-Q in the presence of a base and a solvent to form 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one, wherein R is a protecting group and Q is a leaving group.
  • the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one has formula XXX
  • R is a protecting group
  • the protecting groups may be chosen in accordance with the nature of the functional group, for example as described in Protective Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, John Wiley & Sons Inc, Third Edition, 1999, which reference also describes procedures suitable for replacement of the protecting groups by hydrogen.
  • Preferred protecting groups are phenol protecting groups which are known to those skilled in the art. More preferably, the protecting group is selected from alkyl, alkenyl, aryl, (cycloalkyl)alkyl, arylalkyl, cycloalkyl and a substituted silyl group.
  • the alkyl or aryl group has from 1-24 carbon atoms, more preferably 6-12 carbon atoms.
  • the substituted silyl group is preferably substituted with at least one alkyl group.
  • the protecting group is benzyl or t-butyldimethylsilyl.
  • the compound having the formula R-Q is an alkyl halide or substituted alkyl halide, such as ⁇ -methylbenzyl bromide, methyl chloride, benzylchloride and benzylbromide.
  • Preferred bases include sodium ethoxide, sodium hydroxide, potassium hydroxide, potassium phosphate, potassium carbonate, potassium hydrogencarbonate, caesium carbonate, pyridine and trialkylamines such as triethylamine, tributhylamine and N,N-diisopropylethylamine.
  • a combination of bases may also be used.
  • Preferred bases are potassium hydroxide, potassium carbonate and potassium hydrogencarbonate. Most preferably, the base is N,N-diisopropyl- ethylamine.
  • the solvent in Step (b) is preferably selected from an alkyl acetate, e.g., Ci-Cg-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; lower alkyl alcohols, e.g., G-C6- alkyl alcohols, such as methanol, ethanol, propanol, butanol and pentanol; dimethylformamide; dimethylacetamide; dialkyl ketones, e.g., acetone and methyl isobutyl ketone; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2- methoxyethyl ether and diethylene ether; aqueous solvents, such as water; ionic liquids; and chlorinated solvents, such as methylenechloride.
  • a combination of solvents may
  • a preferred solvent for use in Step (b) is an acetone/water mixture.
  • a preferred volume ratio of acetone to water is from 10:90 to 90:10, respectively. More preferably, the volume ratio of acetone to water is from 20:80 to 80:20, respectively. Most preferably, the volume ratio of acetone to water is about 75:25.
  • the temperature used in Step (b) is preferably from about 20 °C to about 90 °C. More preferably, the temperature is from about 30 °C to about 80 °C; and most preferably from about 50 °C to about 70 °C.
  • the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one is preferably 5-acetyl-8-benzyloxy-(2H)- quinolin-2-one.
  • the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one product may be purified by any of the various techniques known to the art, such as by crystallization.
  • Step (c) the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one that is prepared in Step (b) is reacted with a halogenating agent in the presence of a solvent to form 5-( ⁇ - haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one.
  • the 5-( ⁇ -haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one has formula X as hereinbefore defined wherein R is a protecting group; and X is a halogen.
  • the halogenating agent may be any compound or combination of compounds that provide a halogen atom in situ.
  • Preferred halogenating agents include sodium bromate and hydrobromic acid, bromine, -bromosuccinimide, N-chlorosuccinimide, iodine, chlorine, sulfuryl chloride, benzyltrimethylammoniumdichloroiodate, copper chloride, pyridinium tribromide, tetraalkylammonium tribromide, iodine chloride, hydrochloric acid and an oxidating agent, such as oxone, hydrogen peroxide and monoperoxyphthalic acid.
  • a combination of halogenating agents may also be used. Most preferably, the halogenating agent is benzyltrimethylammoniumdichloroiodate. It is within the scope of the invention to use sulfuryl chloride with methanol.
  • the solvent used in Step (c) is preferably selected from an acid, e.g., carboxylic acids, such as acetic acid, trifluoroacetic acid and propionic acid; an alkyl acetate, e.g., C ⁇ -C ⁇ ;-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydro-furan; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; ionic liquids; and chlorinated solvents, such as methylenechloride.
  • a combination of solvents may also be used.
  • a preferred solvent for use in Step (c) is acetic acid.
  • the temperature used in Step (c) is preferably from about 10 °C to about 160 °C. More preferably, the temperature is from about 20 °C to about 120 °C; and most preferably from about 60 °C to about 75 °C.
  • the 5-( -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one product is preferably 5-( ⁇ -chloroacetyl)-8-benzyloxy-(2H)-quinolin-2-one.
  • the 5-( ⁇ -haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one product may be purified by any of the various techniques known to the art, such as by crystallization.
  • the present invention which provides a process for preparing 5-[(R)-2- (5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(-(i : f)-quinolinone-2-one salts, the 8-substituted oxy-5-((R.)-2-halo-l-hydroxy-ethyl)-(_?H)-quinolin-2-one is converted to the 8- substituted oxy-5-(R.)-oxiranyl-(2H)-quinolin-2-one using steps (d) and (e).
  • Step (d) is carried out in accordance with the description of the first aspect of the process of the present invention. It also corresponds to step (i) of the second aspect of the process of the present invention.
  • Steps (e) through (j) are carried out in accordance with the description of steps (ii) through (vii) of the second aspect of the present invention.
  • Aluminium chloride (93.3 g, 700 mmol, 3.5 eq.) is suspended in 1,2-dichlorobenzene (320 mL). The suspension is maintained at 20-25 °C and 8-hydroxy-(2H)-quinolin-2-one (32.24 g, 200 mmol, 1.0 eq.) is added in 5 portions (40 minutes, IT max. 25 °C). Acetic anhydride (21.4 g, 210 mmol, 1.05 eq.) is slowly added (30 minutes, IT max. 20 °C) and the addition funnel is rinsed with a small amount of 1,2-dichlorobenzene. The suspension is stirred for 30 minutes at 20-25 °C.
  • HPLC control reveals complete conversion to 8-acetoxy- (2H)-quinolin-2-one.
  • HPLC control reveals almost complete conversion to 5-acetyl-8-hydroxy-(2H)-quinolin-2-one (3.1% O-acetyl intermediate, 10.8% ortho-isomer).
  • the reaction mixture is poured hot (80 °C) over water (800 mL). Water (100 ml) is added in the reaction vessel and brought to reflux temperature. After 15 minutes at reflux temperature, the suspension is added to the previous quench suspension.
  • HPLC control reveals complete conversion to 8-acetoxy-(2H)-quinolin- 2-one.
  • HPLC control reveals almost complete conversion to 5-acetyl-8- hydroxy-(2H)-quinolin-2-one (1.8% O-acetyl intermediate, 7.2% ortho-isomer).
  • IT 90°C and poured hot (90 °C) over water (645 mL). Water (100 mL) is added in the reaction vessel and brought to reflux temperature.
  • 5-Acetyl-8-hydroxy-(2 ⁇ )-quinolin-2-one is prepared according to the procedure set forth in Example 1 except that 3 eq. of aluminium chloride is used instead of 3.5 eq. of aluminium chloride. The yield of the title compound is approximately 84%.
  • the product is filtered, washed with acetone/water (1/1, 2 x 8.5 mL) and then with water (4 x 8 mL).
  • the crude product is dried overnight under vacuum (60 °C) . Yield: 10.77 g (91.7%). Purity of the crude product: 99.5%.
  • the product may be recrystallised from acetone/water.
  • a 3 L, 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 40 g 8-(phenylmethoxy)-5-acetyl-(lH)-quinolin-2-one and 400 mL acetic acid under an atmosphere of nitrogen.
  • To this yellow solution is added 94.93 g benzyl-trimethylammoniumdichloroiodate and 200 mL acetic acid.
  • the resulting suspension is heated under stirring to an internal temperature of 65-70 °C.
  • the mixture is stirred at this temperature until an in-process control shows complete conversion to 5-chloroacetyl-8-phenylmethoxy-(27-)-quinolin-2-one.
  • reaction mixture is stirred at an internal temperature of 30 °C until an in process control shows complete conversion to 8-(phenylmethoxy)-5-((R)-2-chloro-l- hydroxy-ethyl)-(2H)-quinolin-2-one. Then the reaction mixture is concentrated in a rotary evaporator, the residue dissolved in 25ml tetrahydrofuran : methanol 9:1 and the product is isolated by addition of 72 ml HCl 0.5 N. Drying over night in a vacuum drier gives 4.76 g of 8-(phenyl-methoxy)-5-((il)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one.
  • reaction mixture is stirred at an internal temperature of 30 °C until an in process control shows complete conversion to 8- (phenylmethoxy)-5-((R)-2-chloro-l-hydroxy-ethyl)-(2i : j r )-quinolin-2-one.
  • 180 ml acetone are added and the internal temp, is raised to 40 °C.
  • the mixture is stirred at 40 °C until an in process control shows ⁇ 0.01%(w/w) formic acid.
  • the reaction mixture is stirred at an internal temperature of 30 °C until an in process control shows complete conversion to 8- (phenylmethoxy)-5-((R)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one.
  • 45 ml acetone are added and the internal temperature is raised to 40 °C.
  • the mixture is stirred at 40 °C until an in process control shows ⁇ 0.01%(w/w) formic acid.
  • 7.9 ml acetic acid are added and the reaction mixture is concentrated in a rotary evaporator to a volume of 75 ml, the residue dissolved in 62.5 ml tetrahydrofuran and the product is isolated by adding 150 ml water and filtration. Drying over night in a vacuum drier gives 9.34 g of 8-(phenyl- methoxy)-5-((R)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-
  • a 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 15 g 8-(phenylmethoxy)-5-((R.)-2-chloro-l-hydroxy- ethyI)-(2H)-quinolin-2-one, 15.72 g potassium carbonate, 375 mL 2-butanone and 3.75 mL water.
  • the mixture is heated under stirring to reflux. Refluxing is maintained until an in- process control shows complete conversion of 8-phenylmethoxy-5-((.
  • the wet filter cake is purified by re-crystallization from 1400 mL of ethanol, which gives 50.08 g pure 8-phenylmethoxy-5-[(R)-2-(5,6-diethyl-indan- 2-ylamino)-l-hydroxy-ethyl]-2H-quinolin-2-one benzoate as a white crystalline powder.
  • a I L hydrogenation vessel is charged with 40 grams of 8-phenylmethloxy-5-[(R)-2-(5,6- diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-2H-quinolin-2-one benzoate and 400 L of acetic acid. Palladium on charcoal 5% (5.44 g) is added and the reaction mass is hydrogenated for 2-8 hours until complete conversion to 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]-8-hydroxy-2H-quinolin-2-one. The mixture is filtered over a pad of filter-aid.
  • the filtrate is concentrated at 50-60 °C under vacuum (100 mbar) to a volume of 70-90 mL. This residue is dissolved in 400 mL of ethanol and heated to 50-60 °C. A solution of 11.6 g maleic acid in 24 mL ethanol is added and the resulting clear solution is seeded at an internal temperature of 50 °C with a suspension of 350 mg micronised 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-hydroxy-2H-quinolin-2-one maleate in 20 mL isopropanol. The product is crystallized by slow cooling to 0-5 °C.
  • reaction mixture contains 68.7% of a compound having formula JV, 7.8% of a compound having formula V, and 12.4% of a compound having formula VI.
  • the reaction mixture is split in equal portions and each portion is individually treated with an acid selected from benzoic acid, maleic acid, succinic acid, fumaric acid, tartaric acid and hydrochloric acid.
  • the percent yield is based on the amount of 8-substituted oxy-5-(R)- oxiranyl-(2H)-quinolin-2-one, and the purity is based on the salt having formula TV and is determined by HPLC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A process for preparing 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(1 H)-quinolin-2-ones or acceptable solvates thereof. The process involves reacting a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((R)-2-halo-l-hydroxy-ethyl)-(1H)-quinolin-2-one, said chiral agent having a formula (I) or (II), wherein M, L, X, R1, R2 and R3 have the meanings as indicated in the specification.

Description

ORGANIC COMPOUNDS
The present invention provides a practical and high-yielding process for the large scale manufacture of 8-substituted oxy-5-((J )-2-halo-l-hydroxy-ethyl)-(iH)-quinolin-2-ones with high enantiomeric purity, which are useful intermediates from which to prepare 5-[(R)-2- (5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2-one salts.
5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(_!H)-quinolin-2-one salts are β-selective adrenoceptor agonists with potent bronchodilator activity. For example, 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2-one maleate is especially useful for treating asthma and chronic obstructive pulmonary disease (COPD).
In a first aspect the invention provides a process for preparing 8-substituted oxy-5-((R)-2- halo-l-hydroxy-ethyl)-(2i1f)-quinolin-2-ones or acceptable solvates thereof comprising reacting a 5-(α-haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((.R)-2-halo-l- hydroxy-ethyl)-(2i-Z)-quinolin-2-one, said chiral agent having a formula I or II
Figure imgf000002_0001
(I) (») wherein
M is Ru, Rh, Ir, Fe, Co or Ni;
L is Cg-C2 -aryl or a C<;-C24-aryl-Cι-Cιo-aliphatic residue, in either case being optionally linked to a polymer;
X is hydrogen or halo;
R1 is a Cι-Cιo-aliphatic, C3-Cιo-cycloaliphatic, C3-Cιo-cycloaliphatic- Cι-Cιo-aliphatic, Cg-
C2 -aryl, Cδ-C2 -aryl- Cα-Cio-aliphatic residue or a 4- to 12-membered heterocyclic group, which, in each case, is optionally linked to a polymer; and
R2 and R3 are phenyl, or R2 and R3 together with the carbon atom to which they are attached form a cyclohexane or cyclopentane ring.
This process provides an efficient process for preparing 8-substituted oxy-5-((R)-2-halo-l- hydroxy-ethyl)-(2H)-quinolin-2-ones, especially 8-phenylmethoxy-5-((. )-2-chloro-l- hydroxy-ethyl)-(2H)-quinolin-2-one, for large scale production with high enantiomeric purity and yield.
Terms used in the specification have the following meanings:
"Halo" or "halogen" as used herein denotes an element belonging to group 17 (formerly group VH) of the Periodic Table of Elements, which may be, for example, fluorine, chlorine, bromine or iodine. Preferably halo or halogen is chlorine, bromine or iodine.
"Cι-Cιo-Aliphatic residue or group" as used herein denotes an acyclic, saturated or unsaturated, non-aromatised hydrocarbon group having up to 10 carbon atoms, for example Cι-Cιo-alkyl, C2-Oo-alkenyl or C2-Cιo-alkynyl. Preferably the G-Cι8-aliphatic residue or group is a Cι-C4-aliphatic residue or group, especially ethyl, propyl or butyl.
"C3-Cιo-Cycloaliphatic residue or group" as used herein denotes a cyclic, saturated or unsaturated, non-aromatised hydrocarbon group having 3 to 10 carbon atoms, for example C3-Cιo-cycloalkyl or C3-C10 cycloalkenyl. Preferably the C3-Cιo-cycloaliphatic residue or group is a C3-C8-cycloaliphatic residue or group, especially C3-Cιo-cycloalkyl or C3-C10- cycloalkenyl.
"C3-Cιo-Cycloaliphatic-Cι-Cιo-aliphatic residue or group" as used herein denotes a Ci-Go- aliphatic residue or group as hereinbefore defined that is substituted by a C3-Cιo-cyclo- aliphatic residue or group as hereinbefore defined, for example C3-Cιo-cycloalkyl-Cι-Go- alkyl, C3-Cιo cycloalkyl-C2-Cιo-alkenyl, C3-Cιo-cycloalkyl-C2-Go-alkynyl, C3-Cιo-cyclo- alkenyl-G-Cio-alkyl, C3-Go-cycloalkenyl-C2-Cιo-alkenyl, C3-Cιo-cycloalkenyl-C -Cιo-alkynyl, C3-Cιo-cycloalkynyl-Cι-Cιo-alkyl, C3-Cιo-cycloalkynyl-C -Cιo-alkenyl or C3-Cιo-cycloalkynyl- C2-Cιo-alkynyl. Preferably the C3-Cιo-cycloaliphatic-Cι-Cιo-aliphatic residue or group is a C3- C8-cycloaliphatic-Cι-C -aliphatic residue or group, especially cyclopropylmethyl.
"C6-C24-Aryl residue or group" as used herein denotes aryl having 6 to 24 carbon atoms. The C6-C24-aryl residue is preferably unsubstituted, however, it may be substituted, for example, by one or more, e.g., two or three, residues, e.g., those selected from halo, Ci-Go- alkyl, halo-G-Cio-alkyl, C2-Cι0-alkenyl, Cι-Cιo-alkoxy, hydroxy, -CHO, G-Cio substituted oxy, C2-Cιo-alkanoyl-oxy, phenyl, phenoxy, halo-substituted-phenoxy, amino, C1-C10- alkylamino, di(Cι-Cιo-alkyl)amino, nitro, cyano and CF3. Preferably the C6-C24~aryl residue or group is a Cή-C2o-aryl residue or group, especially phenyl, isopropylmethylbenzene (cymene), benzene, hexamethylbenzene, mesitylene, 4-chloro-4-phenoxy-phenyl, 4-phenoxy- phenyl, 5-dimethylamino-l-naphthyl, 5-diethylamino-l-naphthyl, 5-nitro-l-naphthyl, 2- nitrophenyl, 3- nitrophenyl, 4-nitrophenyl, 4-vinylphenyl, 4-biphenylyl, 9-anthracenyl, 2- hydroxyphenyl, 3- hydroxyphenyl, 4-hydroxyphenyl, tolyl, phenanthryl, dimethyl- (naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysenyl or perylenyl.
"C6-C2 -Aryl-Cι-Cιo-aliphatic residue or group" as used herein denotes a G-Cio-aliphatic residue or group as hereinbefore defined that is substituted by a C6-C24-aryl residue or. group as hereinbefore defined. Preferably the Cs-C24-aryl-Cι-Cιo-aliphatic residue or group aryl- aliphatic residue is a C6-C2o-aryl-Cι-C -aliphatic residue or group, especially phenyl-G-C - alkyl, phenyl-C2-C4-alkenyl or phenyl-C2-C -alkynyl.
"Ci-Cio-Alkyl" as used herein denotes straight chain or branched alkyl having 1 to 10 carbon atoms. Preferably, G-Qo-alkyl is Cι-C4-alkyl.
"C2-Cιo-Alkenyl" as used herein denotes straight chain or branched alkenyl having 2 to 10 carbon atoms. Preferably, C2-Cιo-alkenyl is C2-C -alkenyl.
"C2-Cιo-AlkynyI" as used herein denotes straight chain or branched alkynyl having 2 to 10 carbon atoms. Preferably, C2-Cιo-alkynyl is C2-C -alkynyl.
"C3-Go-Cycloalkyl" as used herein denotes cycloalkyl having 3 to 10 ring carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, any of which can be substituted by one, two or more Cι-C4-alkyl groups, particularly methyl groups. Preferably, C3-Cιo-cycloalkyl is C3-Cs-cycloalkyl, especially C3-C6-cycloalkyl.
"C3-Cιo-Cycloalkenyl" as used herein denotes cycloalkenyl having 3- to 10-ring carbon atoms, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl or cyclooctenyl, any of which can be substituted by one, two or more Cι-C4-alkyl groups, particularly methyl groups. Preferably, C3-Go-cycloalkenyl is C3-C8-cycloalkenyl, especially C3-C6-cycloalkenyl, in particular, cyclopent-2-en-yl, cyclopent-3-en-yl, cyclohex-2-en-yl or cyclohex-3-en-yl.
"Benzo-C3-Cιrj-cycloalkyl" as used herein denotes C3-Cιo-cycloalkyl as hereinbefore defined attached at two adjacent carbon atoms to a benzene ring. Preferably, benzo-C3-Cιo-cyclo- alkyl is benzo-C3-C8-cycloalkyl, especially, benzocyclohexyl (tetrahydronaphthyl). "C3-Cιo-Cycloalkyl-Cι-Cιo-alkyl" as used herein denotes Ci-Go-alkyl as hereinbefore defined that is substituted by C3-Cιo-cycloalkyl as hereinbefore defined. Preferably, C3-Cιo-cycloalkyl- Ci-Go-alkyl cycloalkylalkyl is C3-C8-cycloaIkyl-Cι-C4-aIkyl.
"C7-C34-Aralkyl" as used herein denotes straight-chain or branched C6-C24-aryl-Cι-Cιo-alkyl. and may be, e.g., one of the G-Cio-alkyl groups mentioned hereinbefore, particularly one of the Cι-C -alkyl groups, substituted by phenyl, tolyl, xylyl or naphthyl. Preferably, C7-C3 - aralkyl is C7-Cι4-aralkyl, especially phenyl-Cι-C4-alkyl, particularly benzyl or 2-phenylethyl.
"Cι-Cιo-Alkoxy" as used herein denotes straight chain or branched alkoxy having 1 to 10 carbon atoms. Preferably, Ci-Go-alkoxy is G-C -alkoxy.
"4- to 12-membered heterocyclic group" as used herein denotes a monovalent heterocyclic group having 4 to 12 carbon atoms and one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur. The 4- to 12-membered heterocyclic group may be, for example, a monocyclic ring with one nitrogen, oxygen or sulfur atom, such as azetidinyl, pyrryl, pyridyl, piperidyl, pyranyl, furyl, tetrahydrofuryl or thienyl, a monocyclic ring with two hetero atoms selected from nitrogen, oxygen and sulfur, such as imidazolyl, pyrimidinyl, piperazinyl, oxazolyl, isoxazolyl, thiazolyl, morpholinyl or thiomorpholinyl, or a bicyclic ring such as benzazole, indole, benzimidazole, indazole, benzothiophene, benzothiazole or benzodioxole. The 4- to 12-membered heterocyclic group can be an unsubstituted or substituted. Preferred substituents on the heterocyclic ring include halo, cyano, hydroxy, carboxy, aminocarbonyl, nitro, Cι-Cιo-alkyl, hydroxy-Cι-C -alkyl, G-Cio-alkoxy, C3-G0- cycloalkyl, Cι-C4-alkylcarbonyl and phenyl-Cι-C4-alkyl. Preferably, the 4- to 12-membered heterocyclic group is a 5- to 8-membered heterocyclic group, especially a monocyclic ring having one or two nitrogen or oxygen atoms such as pyranyl or 2-, 3- or 4-pyridyl, or one nitrogen atom and one oxygen atom, in the ring and optionally substituted on a ring nitrogen atom by Cι-C -alkyl, hydroxy-Cι-C -alkyl, Cι-C4-alkylcarbonyl or phenyl-G-C4-alkyl, or a bicyclic ring such as benzo[l,3]-dioxole. "Halo-Cι-Cιo-alkyl" as used herein denotes straight-chain or branched alkyl as hereinbefore defined that is substituted by one or more, e.g., one, two or three, halogen atoms as hereinbefore defined. Preferably, halo-G-Cio-alkyl is halo-Cι-C4-alkyl, especially where halo is fluorine or chlorine.
"Substituted silyl group" as used herein denotes is preferably a silyl group substituted with at least one Ci-Go-alkyl group as herein defined.
Throughout this specification and in the claims that follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
In a preferred embodiment of the process for preparing 8-substituted oxy-5-((H)-2-halo-l- hydroxy-ethyl)-(2H)-quinolin-2-ones or acceptable solvates thereof the chiral agent has formula I or II as hereinbefore defined, wherein
M is ruthenium;
L is isopropylmethylbenzene, benzene, hexamethylbenzene or mesitylene;
X is hydrogen or halo, preferably chloro;
R1 is phenyl, 2- or 3- or 4-pyridyl, 4'-chloro-4-phenoxy-phenyl, 4-phenoxy-phenyl, 5- dimethylamino-1-naphthyl, 5-nitro-l-naphthyl, 2-, 3-, 4-nitrophenyl, 4-vinylphenyl, 4- biphenylyl, 9-anthracenyl, 2-, 3- or 4-hydroxyphenyl, tolyl, phenanthryl, benzo[l,3]-dioxole, dimethyl(naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysenyl, perylenyl or pyranyl; and
R2 and R3 are both phenyl.
In a particularly preferred embodiment of the process for preparing 8-substituted oxy-5-((il)- 2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-ones or acceptable solvates thereof the chiral agent is a ruthenium based chiral agent, especially RuCl[(iS,2S)-p-TsN-CH(C6H5)CH(C6Hj)- NH2] (r -p -cymene) .
In a second aspect the invention provides a process for preparing 5-[(R)-2-(5,6-diethyl-indan- 2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2-one salts comprising:
(i) reacting a 5-(α-haloacetyl)-8-substituted oxy-(JH)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-substituted oxy-5-((Jl)- 2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one, said chiral agent having a formula I or II as hereinbefore defined;
(ii) treating the 8-substituted oxy-5-((Λ)-2-halo-l-hydroxy-ethyl)-(] i:f)-quinolin-2-one with a base in the presence of a solvent to form a 8-substituted oxy-5-(J )-oxiranyl- (lH)-quinolin-2-one of formula III
Figure imgf000007_0001
wherein R is a protecting group;
(iii) reacting the 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one of formula HI where R is as hereinbefore defined, with 2-amino-(5-6-diethyl)-indan to form a reaction mixture containing compounds having formulae IV, V and VI
Figure imgf000007_0002
wherein R is a protecting group; (iv) treating the reaction mixture prepared in Step (iii) with an acid in the presence of a solvent to form a corresponding salt;
(v) isolating and crystallizing a salt having formula VII
Figure imgf000008_0001
wherein R is a protecting group and A- is an anion;
(vi) removing the protecting group from the salt having formula VII in the presence of a solvent to form a salt having Formula VIII
Figure imgf000008_0002
wherein A" is an anion; and
(vii) treating the salt having formula VIII with an acid in the presence of a solvent to form 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(iH)-quinolin-2- one salt having formula IX
Figure imgf000008_0003
wherein X- is an anion. In a third aspect the invention provides a process for preparing 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-hydroxy-(27^)-quinolin-2-one salts comprising:
(a) reacting
(i) 8-hydroxy-(2H)-quinolin-2-one with an acylating agent and a Lewis acid to form 5-acetyl-8-hydroxy-(2H)-quinolin-2-one; or
(ii) 8-hydroxy-(2H)-quinolin-2-one with an acylating agent to form 8-acetoxy-(2H)- quinolin-2-one, and treating, in-situ, the 8-acetoxy-(iH)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(iH)-quinolin-2-one; or
(iii) 8-acetoxy-(IH)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy- (1 H)-quinolin-2-one;
(b) reacting the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one prepared in Step (a) with a compound having the formula R-Q in the presence of a base and a solvent to form 5- acetyl- 8-substituted oxy-( JH)-quinolin-2-one, wherein R is a protecting group and Q is a leaving group;
(c) reacting the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one with a halogenating agent in the presence of a solvent to form a 5-(α-haloacetyl)-8-substituted oxy-(lH)- quinolin-2-one;
(d) reacting the 5-(α-haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form 8-substituted oxy-5-((il)-2- halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one, said chiral agent having a formula I or II as hereinbefore defined;
(e) treating the 8-substituted oxy-5-((il)-2-halo-l-hydroxy-ethyl)-(j!H)-quinolin-2-one with a base in the presence of a solvent to form a 8-substituted oxy-5-(R)-oxiranyl- (iH)-quinolin-2-one of formula III
Figure imgf000010_0001
wherein R is a protecting group;
( ) reacting the 8-substituted oxy-5-(R)-oxiranyl-(-Η)-quinolin-2-one of formula III where R is as hereinbefore defined, with 2-amino-(5-6-diethyl)-indan to form a reaction mixture containing compounds having formulae IV, V and VI
Figure imgf000010_0002
wherein R is a protecting group;
(g) treating the reaction mixture prepared in Step (f) with an acid in the presence of a solvent to form a corresponding salt;
(h) isolating and crystallizing a salt having formula VII
Figure imgf000011_0001
wherein R is a protecting group and A" is an anion;
(i) removing the protecting group from the salt having formula VII in the presence of a solvent to form a salt having Formula VHI
Figure imgf000011_0002
wherein A" is an anion; and
(j) treating the salt having formula VIII with an acid in the presence of a solvent to a form 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(lH)- quinolin-2-one salt having formula IX
Figure imgf000011_0003
wherein X- is an anion.
In a first aspect the present invention provides a process for preparing 8-substituted oxy-5- ((R)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-ones or acceptable solvates thereof comprising reacting a 5-(α-haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one with a reducing agent in the presence of a chiral agent of formula I or II and a base to form a 8-substituted oxy-5-((ϋ)- 2-halo-l-hydroxy-ethyl)-(lH)-quinolin-2-one. The 5-(α-haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one has formula X
Figure imgf000012_0001
wherein R is a protecting group; and X is a halogen. The halogen is selected from bromine, chlorine, fluorine and iodine. Preferably, the halogen is chlorine.
The 8-substituted oxy-5-((il)-2-halo-l-hydroxy-ethyl)-(iH)-quinolin-2-one has formula XI
Figure imgf000012_0002
OH wherein R is a protecting group; and X is a halogen. The halogen is selected from bromine, chlorine, fluorine and iodine. Preferably, the halogen is chlorine.
The chiral agent is a compound of formula I or II as hereinbefore defined.
M is ruthenium, rhodium, iridium, iron, cobalt or nickel, but it is preferably ruthenium.
L is preferably isopropylmethylbenzene, benzene, hexamethylbenzene or mesitylene, but especially isopropylmethylbenzene. L is optionally linked to a polymer. Suitable polymers include polystyrene (PS), cross-linked PS (J), polyethylene glycol (PEG) or a silica gel residue (Si). Examples are NH-R4, wherein R4 is C(O)(CH2)n-PS or C(O)NH(CH2)n-PS; and -O-Si(Rs)2(CH2)nR6, wherein n is 1-7, R5 is G-C6 alkyl, e.g., ethyl, and R6 is a polystyrene, cross-linked polystyrene, polyethylene glycol or a silica gel residue.
X is hydrogen or halo. It is preferably halo, especially chloro. R1 is preferably phenyl, 2- or 3- or 4-pyridyl, 4'-chloro-4-phenoxy-phenyl, 4-phenoxy-phenyl, 5-dimethylamino-l-naphthyl, 5-nitro-l-naphthyl, 2-, 3-, 4-nitrophenyl, 4-vinylphenyl, 4- biphenylyl, 9-anthracenyl, 2-, 3- or 4-hydroxyphenyl, tolyl, phenanthryl, benzo[l,3]-dioxole, dimethyl(naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysenyl, perylenyl or pyrenyl.
R1 is optionally linked to a polymer. Suitable polymers include polystyrene (PS), cross-linked PS (J), polyethylene glycol (PEG) or a silica gel residue (Si). Examples are NH-R4, wherein R4 is C(O)(CH2)n-PS or C(O)NH(CH2)n-PS; and -O-Si(R5)2(CH2)„R6, wherein n is 1-7, R5 is C1-C6 alkyl, e.g., ethyl, and Re is a polystyrene, cross-linked polystyrene, polyethylene glycol or a silica gel residue.
R2 and R3 are preferably both phenyl.
Chiral agents of formula I and their use in asymmetric hydrogen transfer reactions between alcohols or formic acid and ketones are described in K. Haack et al Agnew. Chem. Int. Ed. Engl. 1997, Vol 36, no.3, pages 285-288, the contents of which is incorporated herein by reference.
The chiral agent of formula I reacts with a base, such as potassium hydroxide or triethylamine, in a solvent such as CH2C12, methanol, dimethylformamide, or dimethylacetamide or a mixture of methanol and dimethylformamide or a mixture of methanol and dimethylacetamide, and upon elimination of a hydrogen halide forms a compound of formula XHI
Figure imgf000013_0001
wherein M, L, R1, R2 and R3 are as hereinbefore defined. The compound of formula XIII reacts with a reducing agent to form the compound of formula I where X is hydrogen.
Preferably the process of the present invention is carried out by adding a chiral agent of formula I as hereinbefore defined where X is halo to the 5-(α-haloacetyl)-8-substituted oxy- (2H)-quinolin-2-one and the reducing agent in the presence of a base such as potassium hydroxide or triethylamine in a solvent such as a mixture of methanol and dimethylformamide or a mixture of methanol and dimethylacetamide. The base converts the chiral agent of formula I where X is halo to the compound of formula XHI which, itself, reacts with the reducing agent to form the chiral agent of formula I where X is hydrogen. As an alternative, the compound of formula I where X is halo is formed in situ by adding a metal- halide dimer such as[RuCl2(p-cymene)]2 and a chiral ligand such as (lS,2S)-(+)-N-p-tosyl-l,2- diphenylethylendiamine separately.
The process of the present invention may also be carried out by adding a chiral agent of formula II to the 5-(α-haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one and the reducing agent in the presence of a base.
Chiral agents of formula II include those that are described in Puentener et al Tetrahedron Letters, 1996, Vol 37, no.45 pages 8165-8168, the contents of which is also incorporated herein by reference. The chiral agent of formula II reacts with a base, such as potassium hydroxide or triethylamine, in a solvent such as CH2C12, methanol, dimethylformamide or dimethylacetamide or a mixture of methanol and dimethylformamide or a mixture of methanol and dimethylacetamide, and upon elimination of a hydrogen halide forms a compound of formula XV
Figure imgf000014_0001
wherein M, L, R2 and R3 are as hereinbefore defined. The compound of formula XV reacts with a reducing agent to form the chiral agent of formula II as hereinbefore defined where X is hydrogen.
The process of the present invention may be carried out by adding a pre-prepared chiral agent of formula LI to the 5-(α-haloacetyl)-8-substituted oxy-( H)-quinolin-2-one and the reducing agent in the presence of a base. For example, a chiral agent of formula II where X is halo is added to the 5-( -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one and the reducing agent in the presence of a base and a solution of potassium hydroxide in a solvent. The base converts the chiral agent of formula II where X is halo to the compound of formula XV which, itself, reacts with the reducing agent to form the chiral agent of formula I where X is hydrogen.As an alternative, the compound of formula LT where X is halo is formed in situ by adding a metal-halide dimer and a chiral ligand separately.
The chiral agent is preferably a pre-prepared compound of formula I, especially a compound of formula XVI
Figure imgf000015_0001
where X is hydrogen or halo. Preferably the chiral agent is RuCl[(iS,2S)-p-TsN- CH(C6H5)CH(C6H5)-NH2](η6-p-cymene).
Alternatively, the chiral agent is a compound of formula I where X is halo that is formed in situ by adding the metal-halide dimer and the chiral ligand separately. For example, RuCl[(2S,25)-p-TsN-CH(C6H5)CH(C6H5)-NH2](η6-ρ-cymene) can be formed by reacting the RuCl2 dimer, [Ru(ηδ-p-cymene)Cl2]2, together with the chiral ligand, 5,S-TsDPEN ((lS,2S)-p- TsNH-CH(C6Hj)CH(C6H5)-NH2), in situ to give RuCl[(2S,2S)-p-TsN-CH(C6H5)CH(C6H5)- NH2](η6-p-cymene), which has formula XVII
Figure imgf000015_0002
using the procedure described in K. Haack et al Agnew. Cbem. Int. Ed. Engl. 1997, Vol 36, no.3, pages 285-288.
Suitable reducing agents include formic acid, primary alcohols and secondary alcohols. Preferred reducing agents include formic acid, 2-propanol and 3-pentanol.
When the chiral agent is a ruthenium based agent, the reducing agent is preferably 2- propanol, 3-pentanol or formic acid. More preferably, the formic acid is used in the presence of an amine, most preferably a tertiary amine such as triethylamine, tributyl amine, 2,2,6,6- tetramethylpiperidine, 1,2,2,6,6-pentamethylpiperidine and N,N-diisopropylethylamine. The reducing agent may also be used as a solvent, especially 2-propanol and most preferably formic acid.
The amount of chiral agent is preferably between about 0.1 to about 10 mole %, especially between about 0.8 and 1 mole %, referring to the compound of formula X.
The reaction is carried out in the presence of a base. The temperature used is preferably from about -10 °C to about 80 °C, but especially from about 0 °C to about 50 °C.
When the reducing agent is formic acid the base is preferably a tertiary amine, for example triethylamine. Triethylamine is preferably used in molar excess to formic acid as this significantly accelerates this reaction. This allows the reaction to be performed at a lower temperature, for example from about 25 °C to about 50 °C, but preferably about 30 °C. This also provides for better enantioselectivities i.e. more of the R isomer of compound of formula X is produced and less of the S isomer of that compound is produced. Preferably the molar ratio of triethylamine to formic acid is from 1:1 to 2:5, but especially about 1:2. When the reducing agent is an alcohol the base is preferably potassium hydroxide or sodium hydroxide.
A solvent is preferably used. The solvent is preferably an alkyl acetate, e.g. a Ci-Cδ-alkyl acetate such as ethyl acetate, isopropyl acetate or butyl acetate, a lower alkyl alcohol, e.g. a Ci-Cg-alkyl alcohol such as methanol, ethanol, propanol, isopropanol, butanol or pentanol; an aliphatic Cι-Cι2-hydro-carbon such as isooctane, heptane; dimethylformamide; dimethylacetamide; an aromatic hydrocarbon such as toluene or benzene; acetonitrile; a heterocycle such as tetrahydrofuran; a dialkyl ether such diisopropyl ether, 2-methoxyethyl ether or diethylene ether; an aqueous solvent such as water; an ionic liquid; or a chlorinated solvent such as methylenechloride. A combination of solvents may also be used. When the chiral agent is a ruthenium based agent the solvent is preferably methanol, methylene- chloride, dimethylformamide or dimethylacetamide. However a combination of methanol and dimethylformamide or a combination of methanol and dimethylacetamide is especially preferred, for example using 90 volumes of methanol with 10 volumes dimethylformamide/ dimethylacetamide.
Preferably the 5-(α-haloacetyl)-8 -substituted oxy-(2H)-quinolin-2-one is reacted with formic acid in the presence of a chiral ruthenium agent and a tertiary amine to form the 8-substituted oxy-5-((. )-2-halo-l-hydroxy-ethyl)-(IH)-quinolin-2-one. The 8-substituted oxy-5-((JR)-2-halo-l- hydroxy-ethyl)-(:.H)-quinolin-2-one of formula XI is preferably 8-phenyl-methoxy-5-((jR)-2- chloro-l-hydroxy-ethyl)-(ifJ)-quinolin-2-one.
The 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(_?H)-quinolin-2-one product is optionally purified by any of the various techniques known to the art, for example by crystallization, and optionally in the presence of charcoal.
As mentioned above, the 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2- ones that are prepared from 5-(α-haloacetyl)-8-substituted oxy-(2H)-quinolin-2-ones in accordance with the first aspect of the present invention may be used to prepare 5-[(R)-2- (5,6-diethyl-indan-2-ylamino)- 1 -hydroxy-ethyl] - 8 -hydroxy-( 1 H)-quinolin-2-one salts. The second aspect of the present invention involves reacting a 5-(α-haloacetyl)-8-substituted oxy- (2H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form an 8-substituted oxy-5-((. )-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one (step i), and its subsequent conversion to a 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8- hydroxy-(2H)-quinolin-2-one salt (steps ii through vii).
Step (i) is carried out as described above in connection with the first aspect of the present invention.
In step (ii) the 8-substituted oxy-5-((JR)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one formed in step (i) is converted to an 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one.
In a preferred embodiment of the invention, the 5-(α-haloacetyl)-8-substituted oxγ-(lH)- quinolin-2-one is reacted with the reducing agent in the presence of the chiral agent and a base to form the 8-substituted oxy-5-(il)-oxiranyl-(2H)-quinolin-2-one in a single step i.e. steps (i) and (ii) are combined. The base is preferably potassium t-butoxide, potassium hydroxide or potassium isopropoxide.
Alternatively, the chiral agent is prepared in situ, for example by adding [Ru(η6-p- cymene)Cl2]2 together with a chiral ligand, such as S,S-TsDPEN {(lS,2S)-p-TsNH- CH(C6H5)CH(C6H5)-NH2) to give RuCl[(25,2S)-p-TsN-CH(C6H5)CH(C6H5)-NH2](η6-p- cymene), which is converted upon addition of a base such as potassium hydroxide or triethylamine, to give RuH[(25,2S)-p-TsN-CH(C6H5)CH(C6Hj)-NH2](η6-p-cymene).
The base used in step (ii) is preferably ethoxide, sodium hydroxide, potassium phosphate, potassium carbonate, potassium hydrogencarbonate or caesium carbonate, but especially potassium carbonate. A combination of bases may also be used.
The solvent used in Step (ii) is preferably an alkyl acetate, e.g. a Ci-Cβ-alkyl acetate such as ethyl acetate, isopropyl acetate or butyl acetate; a lower alkyl alcohol, e.g. a Ci-Cg-alkyl alcohol such as methanol, ethanol, propanol, isopropanol, butanol or pentanol; an aliphatic Cι-Cι2-hydrocarbon such as isooctane, heptane; dimethylformamide; an aromatic hydrocarbon such as toluene or benzene; a dialkyl ketone such as acetone, ethyl methylketone (2- butanone) or methyl isobutyl ketone; acetonitrile; a heterocycle such as tetrahydrofuran; a dialkyl ether such diisopropyl ether, 2-methoxyethyl ether or diethylene ether; an aqueous solvent such as water; an ionic liquid; or a chlorinated solvent such as methylenechloride. A combination of solvents may also be used. A preferred solvent for use in Step (ii) is a combination of acetone and water, however a combination of 2-butanone and water is especially preferred.
The temperature used in Step (ii) is preferably from about 10 °C to about 160 °C. More preferably, the temperature is from about 30 °C to about 90 °C, but especially from about 50 °C to about 80 °C.
The 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one is preferably 8-phenlymethoxy-5- (.R)-oxiranyl-(2H)-quinolin-2-one.
The 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one product is optionally purified by any of the various techniques known to the art, for example by crystallization. Crystallization from toluene or acetone is especially preferred, and is optionally conducted in the presence of charcoal.
In Step (iii) 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one having formula III
Figure imgf000019_0001
where R is a protecting group, is reacted with 2-amino-(5-6-diethyl)-indan to form a reaction mixture containing compounds having formulae IV, V and VI
Figure imgf000019_0002
wherein R is a protecting group;
Preferred protecting groups are phenol protecting groups which are known to those skilled in the art. More preferably, the protecting group is selected from the group consisting of alkyl, aryl, alkoxy, alkenyl, cycloalkyl, benzocycloalkyl, cycloalkylalkyl, aralkyl, heterocyclic, heteroaralkyl, haloalkyl, and a substituted silyl group. Most preferably, the protecting group is benzyl or t-butyldimethylsilyl. Preferably, Step (iii) is conducted in the presence of a solvent. Preferred solvents include: alcohols, e.g., Ci-salkyl alcohols, such as methanol, ethanol, propanol, butanol, and pentanol; aliphatic Cβ-πhydrocarbons, e.g., isooctane, heptane; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydro-furan; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; dimethyl sulfoxide; tetrahydrothiophene 1,1-dioxide, also known as tetramethylene sulfone or as tetramethylene sulfolane; dialkyl carbonate, e.g., dimethyl carbonate and diethyl carbonate; aqueous solvents, such as water; ionic liquids; and chlorinated solvents, such as methylenechloride. A combination of solvents may also be used. More preferably, the solvent is 2-methoxyethyl ether or butanol.
The temperature used in Step (iii) is preferably from about 10 °C to about 160 °C. More preferably, the temperature is from about 30 °C to about 120 °C; and most preferably from about 90 °C to about 120 °C.
Preferably, Step (iii) is conducted with a molar excess of the 2-amino-(5-6-diethyl)-indan with respect to the 8-substituted oxy-5-(R)-oxiranyl-(lH)-quinolin-2-one. Preferably, 1.05 mole equivalent to 3 mole equivalents of 2-amino-(5-6-diethyl)-indan is used with respect to 8- substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one. Most preferably, 1.1 mole equivalents to 1.5 mole equivalents of 2-amino-(5-6-diethyl)-indan is used with respect to 8-substituted oxy- 5-(R)-oxiranyl-(2H)-quinolin-2-one.
The 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one is preferably 8-phenylmethoxy-5- (R)-oxiranyl-(lH)-quinolin-2-one. The 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]- 8 -substituted oxy-(2H)-quinolin-2-one is preferably 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-phenylmethoxy-( 1 H)-quinolin-2-one.
In Step (iv) the reaction mixture prepared in Step (iii) is treated with an acid in the presence of a solvent to form a corresponding salt.
Preferred solvents for use in Step (iv) include: alcohols, e.g. Ci-Gs-alkyl alcohols, such as methanol, ethanol, propanol, butanol, and pentanol; aliphatic Cg-Cn-hydrocarbons, e.g., isooctane, heptane; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; dimethyl sulfoxide; tetrahydrothiophene 1,1-dioxide, also known as tetramethylene sulfone or as tetramethylene sulfolane; dialkyl carbonate, e.g., dimethyl carbonate and diethyl carbonate; aqueous solvents, such as water; ionic liquids; and chlorinated solvents, such as methylenechloride. A combination of solvents may also be used. More preferably, the solvent is ethanol.
The temperature used in Step (iv) is preferably from about -10 °C to about 160 °C. More preferably, the temperature is from about 0 °C to about 120 °C; and most preferably from about 0 °C to about 75 °C.
In Step (v) a salt having Formula VII
Figure imgf000021_0001
is isolated and crystallized, wherein R is a protecting group; and A" is an anion. The anion corresponds to the acid used in Step (iv). The acid used in Step (iv) is preferably a carboxylic acid, such as benzoic acid, maleic acid, succinic acid, fumaric acid, or tartaric acid; or a mineral acid, such as hydrochloric acid. Most preferably, the acid used in Step (iv) is benzoic acid.
The salt having Formula VII is preferably a benzoate salt having formula XIX
Figure imgf000021_0002
wherein R is a protecting group.
More preferably the benzoate salt of formula XIX is a benzoate salt having formula XX
Figure imgf000022_0001
In Step (vi) the protecting group on the salt having formula VII is removed in the presence of a solvent to form a salt having formula VTJI
Figure imgf000022_0002
wherein A- is an anion.
The salt having formula VIII is preferably a benzoate salt having formula XXI
Figure imgf000022_0003
The removal of a protecting group is known to those skilled in the art and depends on the type of protecting group. In one embodiment where the protecting group is benzyl, a preferred method of removing the benzyl group on the salt having formula VII is by treating the salt with hydrogen in the presence of a catalyst. Preferred catalysts include palladium, palladium hydroxide, palladium on activated carbon, palladium on alumina, palladium on carbon powder, platinum, platinum on activated carbon and Raney™ nickel. A combination of catalysts may also be used. Most preferably, the catalyst is palladium on activated carbon.
In one embodiment where the protecting group is t-butyldimethylsilyl, a preferred method of removing the t-butyldimethylsilyl group on the salt having formula VII is by treating the salt with t-butylammonium fluoride or potassium fluoride. The solvent used in Step (vi) is preferably selected from an alkyl acetate, e.g., Cι-C6-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; lower alkyl alkylamines, e.g., Cι-C6-alkylamines; alcohols, e.g., G-Cg-alkyl alcohols, such as methanol, ethanol, propanol, butanol and pentanol; aliphatic Cg-Cι2-hydrocarbons, e.g., isooctane, heptane, dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether, and diethylene ether; an acid, e.g., acetic acid, trifluoroacetic acid, and propionic acid; aqueous solvents, such as water; ionic liquids; and chlorinated solvents, such as methylenechloride. A combination of solvents may also be used. More preferably, the solvent is acetic acid or 2-propanol.
The temperature used in Step (vi) is preferably from about 0 °C to about 70 °C. More preferably, the temperature is from about 10 °C to about 50 °C; and most preferably from about 10 °C to about 30 °C.
The salt having formula VHI is preferably 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl] -8 -hydr oxy- ( 1 H) -quinolin-2-one benzoate.
In Step (vii) the salt having formula VTH is treated with an acid in the presence of a solvent to form a salt having Formula IX
Figure imgf000023_0001
wherein X" is an anion. The anion corresponds to the acid used in Step (vii). The acid used in Step (vii) is preferably a carboxylic acid, such as benzoic acid, maleic acid, succinic acid, fumaric acid, or tartaric acid. Most preferably, the acid used in Step (vii) is maleic acid.
The salt having formula IX is preferably 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]-8-hydroxy-(2icZ)-quinolin-2-one maleate having formula XXII
Figure imgf000024_0001
The solvent used in Step (vii) is preferably selected from an alkyl acetate, e.g., Ci-Cg-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; alcohols, e.g. Ci-Cβ-alkyl alcohols, such as methanol, ethanol, propanol, isopropanol, butanol and pentanol; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; dialkyl ketones, e.g. acetone and methyl isobutyl ketone; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; an acid such as acetic acid and propionic acid; aqueous solvents, such as water; ionic liquids; and chlorinated solvents, such as methylenechloride. A combination of solvents may also be used. More preferably, the solvent is ethanol.
The temperature used in Step (vii) is preferably from about 0 °C to about 70 °C. More preferably, the temperature is from about 10 °C to about 60 °C; and most preferably from about 20 °C to about 50 °C.
As mentioned above, 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy- (2H)-quinolinone-2-one salts can be prepared from 8-hydroxy-(2H)-quinolin-2-one or 8- acetoxy-(2H)-quinolin-2-one. The third aspect of the present invention involves the preparation of 5-(α-haloacetyl)-8-substituted oxy-(lH)-quinolin-2-ones (steps a through c), their reaction with a reducing agent in the presence of a chiral agent to form 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(ϊH)-quinolin-2-ones (step d), and their subsequent conversion to 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)- quinolinone-2-one salts (steps e through j).
In step (a) 8-hydroxy-(lH)-quinolin-2-one or 8-acetoxy-(2H)-quinolin-2-one is converted to form 5-acetyl-8-hydroxy-(j(Jff)-quinolin-2-one. There are three process variants for this step, namely, step (a)(i), step (a)(ii) and step (a)(iii).
In step (a) (i) 8-hydroxy-(2H)-quinolin-2-one is reacted with an acylating agent and a Lewis acid to form 5-acetyl-8-hydroxy-(j[H)-quinolin-2-one. In step (a) (ii) 8-hydroxy-(2H)-quinolin-2-one is reacted with an acylating agent to form 8- acetoxy-(2H)-quinolin-2-one, which is then treated in situ with a Lewis acid to form 5-acetyl- 8-hydroxy-(21J)-quinolin-2-one.
In step (a)(iii) 8-acetoxy-(lH)-quinolin-2-one is reacted with a Lewis acid to form 5-acetyl-8- hydroxy-(lH)-quinolin-2-one.
The 8-hydroxy-(2H)-quinolin-2-one has formula XXIII
(XXIII)
Figure imgf000025_0001
The 5-acetyl-8-hydroxy-(2ff)-quinolin-2-one has formula XXIV
Figure imgf000025_0002
In step (a) the acylating agent, when used, is preferably acetic anhydride or acetyl chloride. The acylating agent is preferably present in an amount of from about 1 molar equivalents to about 1.5 molar equivalents, more preferably about 1.05 molar equivalents, based on the molar equivalents of 8-hydroxy-(2H)-quinolin-2-one.
The Lewis acid is preferably selected from boron trifluoride (BF3), aluminium chloride (A1C13), and titanium tetrachloride (TiCl4). More preferably, the Lewis acid is aluminium chloride. A combination of Lewis acids may also be used.
The Lewis acid is present in an amount of greater than 2 molar equivalents, based on the molar equivalents of 8-hydroxy-(2H)-quinolin-2-one or molar equivalents of 8-acetoxy-(2H)- quinolin-2-one. Preferably, the Lewis acid is present in an amount of about 3 molar equivalents to about 5 molar equivalents, more preferably from about 3.2 molar equivalents to about 4 molar equivalents. In one embodiment of the invention, Step (a) is conducted in the presence of a solvent. In another embodiment of the invention, Step (a) is conducted in the absence of a solvent and in the presence of an ionic compound. The ionic compound is an ionic liquid or an alkaline halide.
Preferably a solvent is used in Step (a). The solvent is preferably a solvent compatible with Friedel-Craft conditions. Such solvents are well-known to those skilled in the art and include chlorobenzene, o-dichlorobenzene, 1,2-ethylene dichloride, aliphatic Cg.Cι2hydrocarbons, e.g., isooctane, heptane and combinations thereof. A combination of solvents may also be used. A preferred solvent for use in Step (a) is o-dichlorobenzene.
Step (a) may be conducted in the absence of a solvent and in the presence of an ionic compound selected from an alkaline halide and an ionic liquid. The alkaline halide is preferably selected from sodium chloride, sodium bromide, lithium chloride and lithium bromide. More preferably, the alkaline halide is sodium chloride. A combination of alkaline halides may also be used.
Ionic liquids are characterized by a positively-charged cation and a negatively-charged anion. Generally, any molten salt or mixture of molten salts is considered an ionic liquid. Ionic liquids typically have essentially no vapour pressure, good heat transfer characteristics, are stable over a wide temperature range and are capable of dissolving a wide range of material in high concentrations. As used herein, "essentially no vapour pressure" means that the ionic liquid exhibits a vapour pressure of less than about 1 mm Hg at 25 °C, preferably less than about 0.1 mm/Hg at 25 °C.
With respect to the type of ionic liquid, a wide variety of possibilities exist. However, the preferred ionic liquids are liquid at relatively low temperatures. Preferably, the ionic liquid has a melting point of less than 250 °C, more preferably less than 100 °C. Most preferably, the ionic liquid has a melting point of less than 30 °C and is a liquid at room temperature. Preferably, the ionic liquid has a viscosity of less than 500 centipoise (cP), more preferably, less than 300 cP, and most preferably less than 100 cP, as determined at 25 °C.
The cation present in the ionic liquid can be a single species or a plurality of different species. Both of these embodiments are intended to be embraced, unless otherwise specified, by the use of the singular expression "cation". The cations of the ionic liquid include organic and inorganic cations. Examples of cations include quaternary nitrogen-containing cations, phosphonium cations and sulfonium cations.
The quaternary nitrogen-containing cations are not particularly limited and embrace cyclic, aliphatic and aromatic quaternary nitrogen-containing cations. Preferably, the quaternary nitrogen-containing cation is an π-alkyl pyridinium, a dialkyl imidazolium or an alkyl- ammonium of the formula RVx NHx, wherein x is 0-3 and each R' is independently an alkyl group having 1-18 carbon atoms. It is believed that unsymmetrical cations can provide for lower melting temperatures. The phosphonium cations are not particularly limited and embrace cyclic, aliphatic and aromatic phosphonium cations. Preferably, the phosphonium cations include those of the formula R"4-x PHx, wherein x is 0-3, and each R" is an alkyl or aryl group, such as an alkyl group having 1-18 carbon atoms or a phenyl group. The sulfonium cations are not particularly limited and embrace cyclic, aliphatic and aromatic sulfonium cations. Preferably, the sulfonium cations include those of the formula R'"3-χ SHx, wherein x is 0-2 and each R'" is an alkyl or aryl group, such as an alkyl group having 1-18 carbon atoms or a phenyl group. Preferred cations include 1-hexylpyridinium, ammonium, imidazolium, l-ethyl-3-methylimidazolium, l-butyl-3-methylimidazolium, phosphonium and -butylpyridinium.
The anion used in the ionic liquid is not particularly limited and includes organic and inorganic anions. Generally the anion is derived from an acid, especially a Lewis acid. The anions are typically metal halides as described in more detail below, boron or phosphorus fluorides, alkylsulfonates including fluorinated alkyl sulfonates, such as nonafluorobutane- sulfonate; and carboxylic acid anions, such as trifluoroacetate and heptafluorobutanoate. The anion is preferably Cb, Br, NO2", NO3", AlCLc, BF4 ~, PF<r, CF3COO-, CF3SO3-, (CF3SO2)2N-, OAc-, CuClr, GaBr4 ~, GaCl4- and SbFg".
Examples of ionic liquids include, but are not limited to, imidazolium salts, pyridium salts, ammonium salts, phosphonium salts and sulphonium salts. Preferred imidazolium salts have formula XXV
Figure imgf000027_0001
wherein Ra and Rb are, independently, selected from the group consisting of a Cι-Cι_- aliphatic group and a C -Cι8-aromatic group; and A- is an anion.
Preferred ammonium salts have formula XXVI
Figure imgf000028_0001
wherein Rc, Rd, Re and Rf are, independently, selected from the group consisting of a Cι-Cι8- aliphatic group and a C4-Ci8-aromatic group; and A- is an anion. Preferably, Rc, Rd, Re and Rf are, independently, selected from the group consisting of ethyl, propyl and butyl.
Preferred phosphonium salts have formula XXVII (XXVII)
Figure imgf000028_0002
wherein Re, Rh, R' and Ri are, independently, selected from the group consisting of a Ci-Ciβ- aliphatic group and a C -Cι8-aromatic group; and A- is an anion. Preferably, Rε, Rh, R1 and Ri are, independently, selected from the group consisting of ethyl and butyl.
Preferred pyridinium salts have formula XXVEI
(XXVIII)
Figure imgf000028_0003
wherein Rk is selected from the group consisting of a Cι-Cι8-aliphatic group and a C -Cι8- aromatic group; and A~ is an anion. Preferably Rk is ethyl or butyl.
Specific examples of ionic liquids include, but are not limited to, l-butyl-3-methylimidazol- ium hexafluorophosphate, l-hexyl-3-methylimidazolium hexafluorophosphate, l-octy-3- methylimidazolium hexafluorophosphate, l-decyl-3-methylimidazolium hexafluorophosphate, l-dodecyl-3-methylimidazolium hexafluorophosphate, l-ethyl-3-methylimidazol- ium &ts((trifluoromethyl)sulphonyl)-imidate, l-hexyl-3-methylimidazolium fots((trifluoro- methyl)sulphonyl)amide, 1-hexylpyridinium tetrafluoroborate, 1-octylpyridinium tetra- fluoroborate, l-butyl-3-methylimidazolium tetrafluoroborate, l-methy-3 -ethyl imidazolium chloride, l-ethyl-3 -butyl imidazolium chloride, l-methy-3 -butyl imidazolium chloride, l-methy-3 -butyl imidazolium bromide, l-methy-3-propyl imidazolium chloride, l-methy-3- hexyl imidazolium chloride, l-methy-3-octyl imidazolium chloride, l-methy-3-decyl imidazolium chloride, l-methy-3-dodecyl imidazolium chloride, l-methy-3-hexadecyl imidazolium chloride, l-methy-3 -octadecyl imidazolium chloride, l-methy-3 -octadecyl imidazolium chloride, ethyl pyridinium bromide, ethyl pyridinium chloride, ethylene pyridinium dibromide, ethylene pyridinium dichloride, butyl pyridinium chloride and benzyl pyridinium bromide.
Preferred ionic liquids are l-ethyl-3-methyl-imidazolium trifluoroacetate, l-butyl-3-methyl- imidazolium trifluoroacetate, l-ethyl-3-methyl-imidazolium trifluoroacetate, l-butyl-3- methyl-imidazolium hexafluorophosphate, l-octyl-3-methyl-imidazolium hexafluorophosphate, l-hexyl-3-methy-imidazolium hexafluorophosphate, l-butyl-3-methyl- imidazolium hexafluorophosphate, l-butyl-3-methyl-imidazolium tetrafluoroborate, 1-ethyl- 3-methyl-imidazolium tetrafluoroborate, l-octyl-3-methyl-imidazolium bromide, l-ethyl-3- methyl-imadazolium trifluorosulfonate, l-butyl-3-methyl-imidazolium trifluorosulfonate,l- butyl-3-methyl-imidazolium trifluoromethanesulfonate, l-ethyl-3-methyl-imidazolium trifluoromethanesulfonate and l-ethyl-3-methyl-imidazolium έ>is-(trifluoromethanesulfonyl)- imidate. Most preferably, the ionic liquid is selected from l-ethyl-3-methyl-imidazolium trifluorosulfonate, l-butyl-3-methylimidazolium chloride, l-octyl-3-methyl-imidazolium hexafluorophosphate and l-hexyl-3-methyl-imidazolium hexafluorophosphate. A combination of ionic liquids may also be used.
Mixtures of ionic compounds and Lewis acids may form reactive liquids at low temperature (see Wasserscheid et al., Angew. Cbem. Int. Ed., Vol. 39, pp. 3772-3789 (2000)).
Preferably, the weight ratio of Lewis acid to ionic compound is from about 10 to about 0.1, respectively. More preferably, the ratio of Lewis acid to ionic compound is from about 3 to about 1, respectively.
The temperature used in Step (a) is preferably from about 0 °C to about 160 °C. More preferably, the temperature is from about 10 °C to about 120 °C; and most preferably from about 15 °C to about 110 °C.
The 5-acetyl-8-hydroxy-(2H)-quinolin-2-one product prepared in Step (a) may also be present with 7-acetyl-8-hydroxy-(2H)-quinolin-2-one having formula XXIX
Figure imgf000030_0001
7-Acetyl-8-hydroxy-(lH)-quinolin-2-one is surprisingly much more soluble than 5-acetyl-8- hydroxy-(ϊH)-quinolin-2-one. The 5-acetyl-8-hydroxy-(2H)-quinolin-2-one may be recovered from the reaction mixture and purified by any of the various techniques known to the art, such as by crystallization or forming a slurry in a solvent. A preferred solvent for forming a slurry is acetic acid.
In the second step, Step (b), the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one that is prepared in Step (a) is reacted with a compound having the Formula R-Q in the presence of a base and a solvent to form 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one, wherein R is a protecting group and Q is a leaving group.
The 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one has formula XXX
Figure imgf000030_0002
wherein R is a protecting group.
Where reference is made herein to protected functional groups or to protecting groups, the protecting groups may be chosen in accordance with the nature of the functional group, for example as described in Protective Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, John Wiley & Sons Inc, Third Edition, 1999, which reference also describes procedures suitable for replacement of the protecting groups by hydrogen. Preferred protecting groups are phenol protecting groups which are known to those skilled in the art. More preferably, the protecting group is selected from alkyl, alkenyl, aryl, (cycloalkyl)alkyl, arylalkyl, cycloalkyl and a substituted silyl group. The alkyl or aryl group has from 1-24 carbon atoms, more preferably 6-12 carbon atoms. The substituted silyl group is preferably substituted with at least one alkyl group. Most preferably, the protecting group is benzyl or t-butyldimethylsilyl.
Preferably, the compound having the formula R-Q is an alkyl halide or substituted alkyl halide, such as α-methylbenzyl bromide, methyl chloride, benzylchloride and benzylbromide. Preferred bases include sodium ethoxide, sodium hydroxide, potassium hydroxide, potassium phosphate, potassium carbonate, potassium hydrogencarbonate, caesium carbonate, pyridine and trialkylamines such as triethylamine, tributhylamine and N,N-diisopropylethylamine. A combination of bases may also be used. Preferred bases are potassium hydroxide, potassium carbonate and potassium hydrogencarbonate. Most preferably, the base is N,N-diisopropyl- ethylamine.
The solvent in Step (b) is preferably selected from an alkyl acetate, e.g., Ci-Cg-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; lower alkyl alcohols, e.g., G-C6- alkyl alcohols, such as methanol, ethanol, propanol, butanol and pentanol; dimethylformamide; dimethylacetamide; dialkyl ketones, e.g., acetone and methyl isobutyl ketone; acetonitrile; heterocycles, such as tetrahydrofuran; dialkyl ethers, e.g., diisopropyl ether, 2- methoxyethyl ether and diethylene ether; aqueous solvents, such as water; ionic liquids; and chlorinated solvents, such as methylenechloride. A combination of solvents may also be used.
A preferred solvent for use in Step (b) is an acetone/water mixture. A preferred volume ratio of acetone to water is from 10:90 to 90:10, respectively. More preferably, the volume ratio of acetone to water is from 20:80 to 80:20, respectively. Most preferably, the volume ratio of acetone to water is about 75:25.
The temperature used in Step (b) is preferably from about 20 °C to about 90 °C. More preferably, the temperature is from about 30 °C to about 80 °C; and most preferably from about 50 °C to about 70 °C.
The 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one is preferably 5-acetyl-8-benzyloxy-(2H)- quinolin-2-one. Optionally, the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one product may be purified by any of the various techniques known to the art, such as by crystallization.
In the third step, Step (c), the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one that is prepared in Step (b) is reacted with a halogenating agent in the presence of a solvent to form 5-(α- haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one.
The 5-(α-haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one has formula X as hereinbefore defined wherein R is a protecting group; and X is a halogen.
The halogenating agent may be any compound or combination of compounds that provide a halogen atom in situ. Preferred halogenating agents include sodium bromate and hydrobromic acid, bromine, -bromosuccinimide, N-chlorosuccinimide, iodine, chlorine, sulfuryl chloride, benzyltrimethylammoniumdichloroiodate, copper chloride, pyridinium tribromide, tetraalkylammonium tribromide, iodine chloride, hydrochloric acid and an oxidating agent, such as oxone, hydrogen peroxide and monoperoxyphthalic acid. A combination of halogenating agents may also be used. Most preferably, the halogenating agent is benzyltrimethylammoniumdichloroiodate. It is within the scope of the invention to use sulfuryl chloride with methanol.
The solvent used in Step (c) is preferably selected from an acid, e.g., carboxylic acids, such as acetic acid, trifluoroacetic acid and propionic acid; an alkyl acetate, e.g., Cι-C<;-alkyl acetates, such as ethyl acetate, isopropyl acetate and butyl acetate; dimethylformamide; dimethylacetamide; aromatic hydrocarbons, such as toluene and benzene; acetonitrile; heterocycles, such as tetrahydro-furan; dialkyl ethers, e.g., diisopropyl ether, 2-methoxyethyl ether and diethylene ether; ionic liquids; and chlorinated solvents, such as methylenechloride. A combination of solvents may also be used. A preferred solvent for use in Step (c) is acetic acid.
The temperature used in Step (c) is preferably from about 10 °C to about 160 °C. More preferably, the temperature is from about 20 °C to about 120 °C; and most preferably from about 60 °C to about 75 °C.
The 5-( -haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one product is preferably 5-(α-chloroacetyl)-8-benzyloxy-(2H)-quinolin-2-one. Optionally, the 5-(α-haloacetyl)-8-substituted oxy-(lH)-quinolin-2-one product may be purified by any of the various techniques known to the art, such as by crystallization.
In the second aspect the present invention, which provides a process for preparing 5-[(R)-2- (5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(-(i:f)-quinolinone-2-one salts, the 8-substituted oxy-5-((R.)-2-halo-l-hydroxy-ethyl)-(_?H)-quinolin-2-one is converted to the 8- substituted oxy-5-(R.)-oxiranyl-(2H)-quinolin-2-one using steps (d) and (e). These steps correspond to steps (i) and (ii) of the process for 8-substituted oxy-5-(R.)-oxiranyl-(2H)- quinolin-2-ones or acceptable solvates thereof that has been described in detail above.
Step (d) is carried out in accordance with the description of the first aspect of the process of the present invention. It also corresponds to step (i) of the second aspect of the process of the present invention.
Steps (e) through (j) are carried out in accordance with the description of steps (ii) through (vii) of the second aspect of the present invention.
The following non-limiting examples illustrate further aspects of the invention.
EXAMPLES
Example 1
Preparation of 5-acetyl-8-hydroxy-( JH)-quinolin-2-one
Aluminium chloride (93.3 g, 700 mmol, 3.5 eq.) is suspended in 1,2-dichlorobenzene (320 mL). The suspension is maintained at 20-25 °C and 8-hydroxy-(2H)-quinolin-2-one (32.24 g, 200 mmol, 1.0 eq.) is added in 5 portions (40 minutes, IT max. 25 °C). Acetic anhydride (21.4 g, 210 mmol, 1.05 eq.) is slowly added (30 minutes, IT max. 20 °C) and the addition funnel is rinsed with a small amount of 1,2-dichlorobenzene. The suspension is stirred for 30 minutes at 20-25 °C. HPLC control reveals complete conversion to 8-acetoxy- (2H)-quinolin-2-one. The mixture is heated to IT = 80 °C while purging the head-space with a stream of nitrogen. HC1 evolution is noticed upon reaching IT = 40 °C. The reaction mixture is stirred for 1 hour at IT = 80 °C. HPLC control reveals almost complete conversion to 5-acetyl-8-hydroxy-(2H)-quinolin-2-one (3.1% O-acetyl intermediate, 10.8% ortho-isomer). The reaction mixture is poured hot (80 °C) over water (800 mL). Water (100 ml) is added in the reaction vessel and brought to reflux temperature. After 15 minutes at reflux temperature, the suspension is added to the previous quench suspension. The mixture is maintained for 15 minutes at IT = 80 °C and then hot filtered. The yellow product is rinsed with water (2 x 200 mL, 50 °C), rinsed with acetone (50 mL) and then dried overnight under vacuum at 70 °C. Yield: 33.32 g (82.0%). Purity: 95-97%.
Example 2
Preparation and purification of 5-acetyl-8-hydroxy-( JH)-quinolin-2-one
8-Hydroxy-(2H)-quinolin-2-one (32.24 g, 200 mmol, 1.0 eq) is suspended in 1,2-dichlorobenzene (300 mL). The suspension is maintained at 20-25 °C and aluminium chloride (93.3 g, 700 mmol, 3.5 eq.) is added in portions (30 minutes, IT max. 25 °C). Acetic anhydride (21.4 g, 210 mmol, 1.05 eq.) is slowly added (30 minutes, IT max. 20 °C) and the addition funnel is rinsed with a small amount of 1,2-dichlorobenzene. The suspension is stirred for 30 minutes at 20-25 °C. HPLC control reveals complete conversion to 8-acetoxy-(2H)-quinolin- 2-one. The mixture is heated to IT = 80 °C while purging the head-space with a stream of nitrogen. HCl evolution is noticed upon reaching IT = 40 °C. The reaction mixture is stirred for 1 hour at IT = 80 °C. HPLC control reveals almost complete conversion to 5-acetyl-8- hydroxy-(2H)-quinolin-2-one (1.8% O-acetyl intermediate, 7.2% ortho-isomer). The reaction mixture is heated to IT = 90°C and poured hot (90 °C) over water (645 mL). Water (100 mL) is added in the reaction vessel and brought to reflux temperature. After 15 minutes at reflux temperature, the suspension is added to the previous quench suspension. The mixture is maintained for 15 minutes at IT = 80 °C and is hot filtered. The yellow product is rinsed with water (2 x 200 mL, 50 °C). The crude product (70.1 g) is suspended in acetic acid (495 mL) and the suspension is heated to reflux temperature for 30 minutes. The suspension is cooled down to IT = 20°C and then filtered. The product is washed with acetic acid/water 1/1 (60 mL) and washed with water (5 x 100 mL) before being dried at 70°C under vacuum to yield the title compound in 75% yield (31.48 g) and with 99.9% purity.
Example 3
Preparation of 5-acetyl-8-hydroxy-( lH)-qumolin-2-one
5-Acetyl-8-hydroxy-(2Η)-quinolin-2-one is prepared according to the procedure set forth in Example 1 except that 3 eq. of aluminium chloride is used instead of 3.5 eq. of aluminium chloride. The yield of the title compound is approximately 84%.
Example 4
Preparation of 5-acetyl-8-hydroxy-(j(H)-qumolin-2-one from 8-acetoxy-( lH)-quinoliri-2-one
8-Acetoxy-(2H)-quinolin-2-one (6.1 g, 30 mmol, 1.0 eq.) is suspended in 1,2-dichlorobenzene (80 mL). The suspension is warmed to 80 °C and aluminium chloride (12.0 g, 90 mmol, 3.0 eq.) is added in portions. The reaction is stirred for 1 hour at IT = 80 °C. HPLC control reveals almost complete conversion to 5-acetyl-8-hydroxy-(;-H)-quinolin~2-one. The reaction mixture is poured hot (80 °C) over water (100 mL). Water (30 mL) is added in the reaction vessel and then brought to reflux temperature. After 15 minutes at reflux temperature, the suspension is added to the previous quench suspension. The mixture is maintained for 15 minutes at IT = 80 °C and then hot filtered. The yellow product is rinsed with water (2 x 50 mL, 50 °C) and then dried overnight under vacuum at 80 °C. Yield: 4.32 g (79.0%). Purity: 95%.
Example 5
Preparation of 5-acetyl-8-benzyloxy-( JH)-quinolin-2-one
[Crude 5-acetyl-8-hydroxy-(2Η)-quinolin-2-one (8.13 g, 40 mmol, 1.0 eq.) is added to N- N,diisopropylethylamine (6.46 g, 50 mmol, 1.25 eq.) and acetone (64 mL). The suspension is heated to reflux temperature and water is added (8.2 mL). Benzylbromide (7.52 g, 44 mmol, 1.10 eq.) is added drop-wise and the reaction is maintained for 6-7 hours at reflux temperature until all starting material has reacted. Water (20 mL) is added at IT = 58 °C and the mixture is cooled down to 20-25 °C. The product is filtered, washed with acetone/water (1/1, 2 x 8.5 mL) and then with water (4 x 8 mL). The crude product is dried overnight under vacuum (60 °C) . Yield: 10.77 g (91.7%). Purity of the crude product: 99.5%. The product may be recrystallised from acetone/water.
Example 6
Preparation of 5-(α-chloroacetyl)-8-(phenylmethoxy)- (lH)-quinolin-2-one
A 3 L, 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 40 g 8-(phenylmethoxy)-5-acetyl-(lH)-quinolin-2-one and 400 mL acetic acid under an atmosphere of nitrogen. To this yellow solution is added 94.93 g benzyl-trimethylammoniumdichloroiodate and 200 mL acetic acid. The resulting suspension is heated under stirring to an internal temperature of 65-70 °C. The mixture is stirred at this temperature until an in-process control shows complete conversion to 5-chloroacetyl-8-phenylmethoxy-(27-)-quinolin-2-one. The mixture is then cooled to a temperature of 40-45 °C. Within 30-60 minutes, 400 mL water is added. The resulting suspension is stirred at 20-25°C for 30-60 minutes and then 300 g of a 5%(w/w) solution of NaHSO3 in water is added within 30 to 60 minutes at a temperature of 15 to 20 °C. At the end of the addition a test for the presence of I2 is negative. Crude 5-(α-chloroacetyl)-8- (phenylmethoxy)- (2H)-quinolin-2-one is isolated by filtration and purified by crystallisation from acetic acid. Drying in a vacuum oven at 50°C gives 39.3 g of pure 5-(α-chloroacetyl)-8- (phenylmethoxy)- (2H)-quinolin-2-one.
Example 7
Preparation of 8-(phenylmethoxy)-5-((l^)-2-chloro-l-hydroxy-ethyl)-( lH)-quinolin-2-one
In a 3-necked flask 11 mg (lS,2S)-(+)-N-p-tosyl-l,2-diphenylethylendiamine and 9 mg [RuCl2(p-cymene)]2 are dissolved inlO ml of methanol/dimethylformamide (95/5 v/v). To the resulting orange solution 9μl triethylamine are added and the mixture is heated to reflux for 1 hour 30 minutes. After cooling to 30°C, 1 g 8-Benzyloxy-5-(2-chloroacetyl)-lH-quinolin- 2-one followed by 10 ml of methanol/dimethylformamide (95/5 v/v) are added. A mixture of ' 0.69 ml formic acid and 5.1 ml triethylamine is added and the resulting suspension is stirred until an in process control shows complete conversion to 8-(phenyl-methoxy)-5-((Λ)-2-chloro- l-hydroxy-ethyl)-(2H)-quinolin-2-one. The reaction mixture is then concentrated in a rotary evaporator, the residue dissolved in 2.5 ml tetrahydrofuran : methanol 9:1 and the product is isolated by addition of 7.2 ml HCl 0.5 N. Drying over night in a vacuum drier gives 993 mg of 8-(phenylmethoxy)-5-((JR)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one.
Alternatively, in a 3-necked flask are placed 5 g of 8-(phenylmethoxy)-5-chloroacetyl-(2H- quinolin-2-one, 97 mg of RuCl[(2S,2S)-p-TsN-CH(C6H )CH(C6H5)-NH2](η6-p-cymene) and 100 mL of a mixture methanol : dimethylformamide 95:5 under an atmosphere of nitrogen. A pre-formed mixture of 4.21 g formic acid and 18.52 g triethylamine is added at 30 - 34 °C under agitation. The reaction mixture is stirred at an internal temperature of 30 °C until an in process control shows complete conversion to 8-(phenylmethoxy)-5-((R)-2-chloro-l- hydroxy-ethyl)-(2H)-quinolin-2-one. Then the reaction mixture is concentrated in a rotary evaporator, the residue dissolved in 25ml tetrahydrofuran : methanol 9:1 and the product is isolated by addition of 72 ml HCl 0.5 N. Drying over night in a vacuum drier gives 4.76 g of 8-(phenyl-methoxy)-5-((il)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one.
As a further alternative, in a 3-necked flask are placed 40 g of 8-(phenylmethoxy)-5- chloroacetyl-(lH)-quinolin-2-one, 776 mg of RuCl[(2S,2S)-p-TsN-CH(CsH5)CH(C6H )- NH2](η6-p-cymene) and 800 ml of a mixture methanol : dimethylformamide 9:1 under an atmosphere of nitrogen. A pre-formed mixture of 9.2 ml formic acid and 68 ml triethylamine is added at 10 - 30 °C under agitation. The reaction mixture is stirred at an internal temperature of 30 °C until an in process control shows complete conversion to 8- (phenylmethoxy)-5-((R)-2-chloro-l-hydroxy-ethyl)-(2i:jr)-quinolin-2-one. In order to consume any remaining formic acid, 180 ml acetone are added and the internal temp, is raised to 40 °C. The mixture is stirred at 40 °C until an in process control shows <0.01%(w/w) formic acid. Then 31.4ml Acetic acid are added and the reaction mixture is concentrated in a rotary evaporator to a volume of 300ml, the residue dissolved in 250ml tetrahydrofuran and the product is isolated by addition of 720ml water. Drying over night in a vacuum drier gives 37g of 8-(phenyl-methoxy)-5-((jR)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one.
As a yet further alternative, in a 3-necked flask are placed 10 g of 8-(phenylmethoxy)-5- chloroacetyl-(2H)-quinolin-2-one, 194.2 mg of Ruα[(2S, S)-p-TsN-CH(G;H5)CH(C<;H5)- NH2](r|<;-p-cymene) and 200 ml of a mixture methanol : dimethylacetamide 9:1 under an atmosphere of nitrogen. A preformed mixture of 2.3 ml formic acid and 17 ml triethylamine is added at 10 - 30 °C under agitation. The reaction mixture is stirred at an internal temperature of 30 °C until an in process control shows complete conversion to 8- (phenylmethoxy)-5-((R)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one. Then 45 ml acetone are added and the internal temperature is raised to 40 °C. The mixture is stirred at 40 °C until an in process control shows <0.01%(w/w) formic acid. Then 7.9 ml acetic acid are added and the reaction mixture is concentrated in a rotary evaporator to a volume of 75 ml, the residue dissolved in 62.5 ml tetrahydrofuran and the product is isolated by adding 150 ml water and filtration. Drying over night in a vacuum drier gives 9.34 g of 8-(phenyl- methoxy)-5-((R)-2-chloro-l-hydroxy-ethyl)-(2H)-quinolin-2-one.
Example 8
Preparation of 8-(phenylmethoxy)-5-( jR)-oxiranyl-( l.H)-quinolin-2-one
A 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 15 g 8-(phenylmethoxy)-5-((R.)-2-chloro-l-hydroxy- ethyI)-(2H)-quinolin-2-one, 15.72 g potassium carbonate, 375 mL 2-butanone and 3.75 mL water. The mixture is heated under stirring to reflux. Refluxing is maintained until an in- process control shows complete conversion of 8-phenylmethoxy-5-((. )-2-chloro-l-hydroxy- ethyl)-(2H)-quinolin-2-one to 8-phenylmethoxy-5-(i?.)-oxiranyl-(j[H)-quinolin-2-one. When the reaction is complete, the hot reaction mixture is filtered to remove the inorganic salts. The residue is washed with several portions of 2-butanone, and the combined mother liquor and 2-butanone washings are concentrated to a volume of about 180 mL. To the resulting suspension is added 210 mL toluene. This suspension is again heated to IT = 70 to 80- °C. 8- (phenylmethoxy)-5-(. )-oxiranyl-(2H)-quinolin-2-one is isolated by cooling down to 0 °C, filtration and crystallisation of the crude product from toluene. Drying over night at 50°C gives 11 g of 8-(phenylmethoxy)-5-(R)-oxiranyl-(2H)-quinolin-2-one. Alternatively, a 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 50 g 8-(phenylmethoxy)-5-((. )-2-chloro-l- hydroxy-ethyl)-(!H)-quinolin-2-one, 52.42 g potassium carbonate, 2.5 L acetone and 25 mL water. The mixture is heated under stirring to reflux. Refluxing is maintained until an in- process control shows complete conversion of 8-phenylmethoxy-5-((R)-2-chloro-l-hydroxy- ethyl)-(2H)-quinolin-2-one to 8-phenylmethoxy-5-(il)-oxiranyl-(2H)-quinolin-2-one. When the reaction is complete, the hot reaction mixture is filtered to remove the inorganic salts. The- residue is washed with several portions of acetone, and the combined mother liquor and acetone washings are concentrated to a volume of about 450 ml. To the resulting suspension are added 235 mL heptanes. This suspension is stirred for 2-3 hours at 0 - 5°C and the crude product is isolated by filtration and crystallised from toluene. Drying over night at 50°C gives 37g of 8-(phenylmethoxy)-5-(R)-oxiranyl-(2H)-quinolin-2-one.
Example 9
Preparation of 5-[(R)-2-(5.6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-phenylmethoxy-
(iH)-quinolin-2-one benzoate
A I L, 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 30.89 grams of 2-amino-5,6-diethylindan and diethylene glycol dimethyl ether (93 mL). To this solution is added 36.4 grams of 8-phenyl-methoxy-5- (R)-oxiranyl-2H-quinolin-2-one. The resulting suspension is heated to a temperature of 110 °C and stirred at this temperature for 15 hours. The resulting brown solution is cooled to 70 °C. At 70 °C, 210 mL of ethanol is added followed by a solution of 30.3 grams of benzoic acid in 140 mL of ethanol. The solution is cooled to 45-50 °C and seeded. The suspension is cooled to 0-5 °C. The crude 8-phenylmethoxy-5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l- hydroxy-ethyl]-l.Hr-quinolin-2-one benzoate is isolated by filtration and washed with 150 mL of ethanol in three portions. The wet filter cake is purified by re-crystallization from 1400 mL of ethanol, which gives 50.08 g pure 8-phenylmethoxy-5-[(R)-2-(5,6-diethyl-indan- 2-ylamino)-l-hydroxy-ethyl]-2H-quinolin-2-one benzoate as a white crystalline powder.
Example 10
Preparation of 5-[(R)-2-(5.6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-lH- quinolin-2-one maleate
A I L hydrogenation vessel is charged with 40 grams of 8-phenylmethloxy-5-[(R)-2-(5,6- diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-2H-quinolin-2-one benzoate and 400 L of acetic acid. Palladium on charcoal 5% (5.44 g) is added and the reaction mass is hydrogenated for 2-8 hours until complete conversion to 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]-8-hydroxy-2H-quinolin-2-one. The mixture is filtered over a pad of filter-aid. The filtrate is concentrated at 50-60 °C under vacuum (100 mbar) to a volume of 70-90 mL. This residue is dissolved in 400 mL of ethanol and heated to 50-60 °C. A solution of 11.6 g maleic acid in 24 mL ethanol is added and the resulting clear solution is seeded at an internal temperature of 50 °C with a suspension of 350 mg micronised 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-hydroxy-2H-quinolin-2-one maleate in 20 mL isopropanol. The product is crystallized by slow cooling to 0-5 °C. Filtration and washing with 50 mL of ethanol followed by 25 mL of isopropanol provides 65 g crude 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-l-hydroxy-ethyl]-8-hydroxy-2H-quinolin-2-one maleate which is further purified by crystallization from 1.36 L of ethanol. This gives 24.3 g pure 5-[(R)-2-(5,6-diethyl-indan- 2-ylamino)-l~hydroxy-ethyl]-8-hydroxy-2H-quinolin-2-one maleate as a white crystalline powder.
Example 11
Purity and Yield of Different Salts of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy- ethyl]-8-substituted oxy-( JH)-quinolin-2-one
A I L, 4-necked flask equipped with a mechanical stirrer, thermometer, addition funnel and refluxing condenser is charged with 30.89 grams of 2-amino-5,6-diethylindan and diethylene glycol dimethyl ether. To this solution is added 36.4 grams of 8-phenyl-methoxy-5-(R)-oxi- ranyl-2H-quinolin-2-one. The resulting suspension is heated to a temperature of 110 °C and stirred at this temperature for 15 hours. The resulting brown solution is cooled to 70 °C.
The reaction is conducted as follows:
Figure imgf000039_0001
where R is Bn. As determined by HPLC , the reaction mixture contains 68.7% of a compound having formula JV, 7.8% of a compound having formula V, and 12.4% of a compound having formula VI. The reaction mixture is split in equal portions and each portion is individually treated with an acid selected from benzoic acid, maleic acid, succinic acid, fumaric acid, tartaric acid and hydrochloric acid. The results are summarized in Table 1 as follows:
TABLE 1
Figure imgf000040_0001
As set forth in Table 1, the percent yield is based on the amount of 8-substituted oxy-5-(R)- oxiranyl-(2H)-quinolin-2-one, and the purity is based on the salt having formula TV and is determined by HPLC.

Claims

1. A process for preparing 8-substituted oxy-5-((J )-2-halo-l-hydroxy-ethyl)-(2i )- quinolin-2-ones or acceptable solvates thereof comprising reacting a 5-(α-haloacetyl)-8- substituted oxy-(IH)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((il)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one, said chiral agent having a formula I or II
Figure imgf000041_0001
(i) CD wherein
M is Ru, Rh, Ir, Fe, Co or Ni;
L is C6-C2 -aryl or a C6-C24-aryl-G-Cιo-aliphatic residue, in either case being optionally linked to a polymer;
X is hydrogen or halo;
R1 is a Cι-Cιo-aliphatic, C3-Cιo-cycloaliphatic, C3-Go-cycloaliphatic- G-Cio-aliphatic, Cg-
C2 -aryl, Cέ-C2 -aryl- Cι-Cιo-aliphatic residue or a 4- to 12-membered heterocyclic group, which, in each case, is optionally linked to a polymer; and
R2 and R3 are phenyl, or R2 and R3 together with the carbon atom to which they are attached form a cyclohexane or cyclopentane ring.
2. A process according to Claim 1, wherein the chiral agent has formula I or II, wherein
M is ruthenium;
L is isopropylmethylbenzene, benzene, hexamethylbenzene or mesitylene;
X is hydrogen or halo;
R1 is phenyl, 2- or 3- or 4-pyridyl, 4'-chloro-4-phenoxy-phenyl, 4-phenoxy-phenyl, 5- dimethylamino-1-naphthyl, 5-nitro-l-naphthyl, 2-, 3-, 4-nitrophenyl, 4-vinylphenyl, 4- biphenylyl, 9-anthracenyl, 2-, 3- or 4-hydroxyphenyl, tolyl, phenanthryl, benzo[l,3]-dioxole, dimethyl(naphthalene-l-yl)-amine, mono to tristrifluoromethylphenyl, chrysenyl, perylenyl or pyranyl; and R2 and R3 are both phenyl.
3. A process according to Claim 1 or 2, wherein the chiral agent is a ruthenium based agent and the reducing agent is selected from the group consisting of 2-propanol, 3-pentanol and formic acid.
4. A process according to any preceding Claim, wherein the chiral agent is RuCl[(2S,2S)- p-TsN-CH(C6H5)CH(C6H5)-NH2](η6-p-cymene).
5. A process according to any preceding Claim, wherein the temperature used is from -10 °C to 80 °C, preferably from 0 °C to 50 °C.
6. A process according to any preceding Claim, wherein the 8-substituted oxy-5-((R)-2- halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one is 8-phenylmethoxy~5-((.R)-2-chloro-l-hydroxy- ethyl)-( 1 H)-quinolin-2-one.
7. A process for preparing 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8- hydroxy-(_ H)-quinolinone-2-one salts comprising:
(i) reacting a 5-(α-haloacetyl)-8-substituted oxy-(2H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-substituted oxy-5-((.R)- 2-halo-l-hydroxy-ethyl)-(lH)-quinolin-2-one, said chiral agent having a formula I or II as hereinbefore defined;
(ϋ) treating the 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(2H)-quinolin-2-one with a base in the presence of a solvent to form a 8-substituted oxy-5-(R)-oxiranyl- (2H)-quinolin-2-one of formula III
Figure imgf000042_0001
wherein R is a protecting group; (iii) reacting the 8-substituted oxy-5-(R)-oxiranyl-(liϊ)-quinolin-2-one of formula TR where R is as hereinbefore defined, with 2-amino-(5-6-diethyl)-indan to form a reaction mixture containing compounds having formulae IV, V and VI
Figure imgf000043_0001
wherein R is a protecting group;
(iv) treating the reaction mixture prepared in Step (iii) with an acid in the presence of a solvent to form a corresponding salt;
(v) isolating and crystallizing a salt having formula VII
Figure imgf000043_0002
wherein R is a protecting group and A" is an anion;
(vi) removing the protecting group from the salt having formula VII in the presence of a solvent to form a salt having Formula VIII
Figure imgf000044_0001
wherein A- is an anion; and
(vii) treating the salt having formula Vfll with an acid in the presence of a solvent to form 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)-quinolin-2- one salt having formula IX
Figure imgf000044_0002
wherein X" is an anion.
8. A process according to Claim 7, wherein the reducing agent is formic acid.
9. A process according to Claim 7 or 8, wherein the base used in step (ii) is ethoxide, sodium hydroxide, potassium phosphate, potassium carbonate, potassium hydrogencarbonate, caesium carbonate or a mixture thereof.
10. A process for preparing 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8- hydroxy-(2H)-quinolin-2-one salts comprising:
(a) reacting
(i) 8-hydroxy-(2H)-quinolin-2-one with an acylating agent and a Lewis acid to form 5-acetyl- 8 -hydr oxy- ( 1 H) -quinolin-2-one; or
(ii) 8-hydroxy-(2H)-quinolin-2-one with an acylating agent to form 8-acetoxγ-(lH)- quinolin-2-one, and treating, in-situ, the 8-acetoxy-(2H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(2H)-quinolin-2-one; or (iii) 8-acetoxy-(l"H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy- ( 1 JJ)-quinolin-2-one;
(b) reacting the 5-acetyl-8-hydroxy-(2H)-quinolin-2-one prepared in Step (a) with a compound having the formula R-Q in the presence of a base and a solvent to form 5- acetyl-8-substituted oxy-(2H)-quinolin-2-one, wherein R is a protecting group and Q is a leaving group;
(c) reacting the 5-acetyl-8-substituted oxy-(2H)-quinolin-2-one with a halogenating agent in the presence of a solvent to form a 5-(α-haloacetyl)-8-substituted oxγ-(lH)- quinolin-2-one;
(d) reacting the 5-(α-haloacetyl)-8-substituted oxy-(2Η)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form 8-substituted oxy-5-((R)-2- halo-l-hydroxy-ethyl)-(_(H)-quinolin-2-one, said chiral agent having a formula I or II as hereinbefore defined;
(e) treating the 8-substituted oxy-5-((. )-2-halo-l-hydroxy-ethyl)-(2.H)-quinolin-2-one with a base in the presence of a solvent to form a 8-substituted oxy-5-(.R)-oxiranyi- (2H)-quinolin-2-one of formula IE
Figure imgf000045_0001
wherein R is a protecting group;
(f) reacting the 8-substituted oxy-5-(R)-oxiranyl-(2H)-quinolin-2-one of formula III where R is as hereinbefore defined, with 2-amino-(5-6-diethyl)-indan to form a reaction mixture containing compounds having formulae TV, V and VI
Figure imgf000046_0001
wherein R is a protecting group;
(g) treating the reaction mixture prepared in Step (f) with an acid in the presence of a solvent to form a corresponding salt;
(h) isolating and crystallizing a salt having formula VII
Figure imgf000046_0002
wherein R is a protecting group and A- is an anion;
(i) removing the protecting group from the salt having formula VII in the presence of a solvent to form a salt having Formula VEH
Figure imgf000047_0001
wherein A- is an anion; and
(j) treating the salt having formula VHI with an acid in the presence of a solvent to a form 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-(2H)- quinolin-2-one salt having formula IX
Figure imgf000047_0002
wherein X" is an anion.
11. A process for preparing 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(2H)- quinolin-2-ones or acceptable solvates thereof substantially as herein described with reference to any one of the Examples.
12. A process for preparing 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8- hydroxy-(2H)-quinolin-2-one salts substantially as herein described with reference to any one of the Examples.
PCT/EP2005/006686 2004-06-22 2005-06-21 Enantioselektive preparation of quinoline derivative WO2005123684A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
KR1020067026958A KR101179302B1 (en) 2004-06-22 2005-06-21 Enantioselektive Preparation of Quinoline Derivative
DE602005018076T DE602005018076D1 (en) 2004-06-22 2005-06-21 ENANTIOSELECTIVE PREPARATION OF CHINOLIN DERIVATIVES
AU2005254698A AU2005254698B2 (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivative
PL05770221T PL1791820T3 (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivatives
BRPI0512298-8A BRPI0512298A (en) 2004-06-22 2005-06-21 organic compounds
AT05770221T ATE450512T1 (en) 2004-06-22 2005-06-21 ENANTIOSELECTIVE PRODUCTION OF QUINOLINE DERIVATIVES
NZ551276A NZ551276A (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivatives
CA2566388A CA2566388C (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivative
CN2005800195899A CN1968927B (en) 2004-06-22 2005-06-21 Method for enantiomer selective preparation for quinoline derivative
JP2007517180A JP5064214B2 (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivatives
DK05770221.9T DK1791820T3 (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivatives
US11/569,140 US20090054653A1 (en) 2004-06-22 2005-06-21 Enantioselektive preparation of quinoline derivative
MXPA06014695A MXPA06014695A (en) 2004-06-22 2005-06-21 Organic compounds.
EP05770221A EP1791820B1 (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivatives
IL179600A IL179600A (en) 2004-06-22 2006-11-27 Enantioselective preparation of quinoline derivative
TNP2006000408A TNSN06408A1 (en) 2004-06-22 2006-12-08 Enantioselektive preparation of quinoline derivative
NO20070400A NO339079B1 (en) 2004-06-22 2007-01-22 Processes for the preparation of 8-substituted oxy-5 - ((R) -2-halo-1-hydroxyethyl) - (1H) -quinolin-2-one and 5 - [(R) -2- (5,6) -diethyl-indan-2-ylamino) -1-hydroxy-ethyl] -8-hydroxy- (1H) -quinolin-2-one salts
HK07110434.6A HK1105121A1 (en) 2004-06-22 2007-09-25 Enantioselective preparation of quinoline derivatives
HR20100087T HRP20100087T1 (en) 2004-06-22 2010-02-18 Enantioselective preparation of quinoline derivatives
US13/461,204 US20120220775A1 (en) 2004-06-22 2012-05-01 Enantioselective preparation of quinoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413960.6A GB0413960D0 (en) 2004-06-22 2004-06-22 Organic compounds
GB0413960.6 2004-06-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/461,204 Continuation US20120220775A1 (en) 2004-06-22 2012-05-01 Enantioselective preparation of quinoline derivatives

Publications (2)

Publication Number Publication Date
WO2005123684A2 true WO2005123684A2 (en) 2005-12-29
WO2005123684A3 WO2005123684A3 (en) 2006-06-01

Family

ID=32799952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006686 WO2005123684A2 (en) 2004-06-22 2005-06-21 Enantioselektive preparation of quinoline derivative

Country Status (33)

Country Link
US (2) US20090054653A1 (en)
EP (1) EP1791820B1 (en)
JP (1) JP5064214B2 (en)
KR (1) KR101179302B1 (en)
CN (1) CN1968927B (en)
AR (2) AR049553A1 (en)
AT (1) ATE450512T1 (en)
AU (1) AU2005254698B2 (en)
BR (1) BRPI0512298A (en)
CA (1) CA2566388C (en)
CY (1) CY1109884T1 (en)
DE (1) DE602005018076D1 (en)
DK (1) DK1791820T3 (en)
EC (1) ECSP067100A (en)
ES (1) ES2337273T3 (en)
GB (1) GB0413960D0 (en)
HK (1) HK1105121A1 (en)
HR (1) HRP20100087T1 (en)
IL (1) IL179600A (en)
MA (1) MA28687B1 (en)
MX (1) MXPA06014695A (en)
MY (1) MY142051A (en)
NO (1) NO339079B1 (en)
NZ (1) NZ551276A (en)
PE (1) PE20060304A1 (en)
PL (1) PL1791820T3 (en)
PT (1) PT1791820E (en)
RU (1) RU2383534C2 (en)
SI (1) SI1791820T1 (en)
TN (1) TNSN06408A1 (en)
TW (1) TWI347317B (en)
WO (1) WO2005123684A2 (en)
ZA (1) ZA200609257B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025816A1 (en) * 2006-08-31 2008-03-06 Novartis Ag Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
WO2012007539A1 (en) 2010-07-14 2012-01-19 Novartis Ag Ip receptor agonist heterocyclic compounds
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
WO2012106575A1 (en) 2011-02-04 2012-08-09 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105066A1 (en) 2012-01-13 2013-07-18 Novartis Ag Salts of an ip receptor agonist
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2014008640A1 (en) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 Indacaterol intermediate and method for synthesizing indacaterol
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
WO2014097151A2 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
WO2014141135A1 (en) 2013-03-14 2014-09-18 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
WO2014139485A1 (en) 2013-03-15 2014-09-18 Zentiva, K.S. A method for the preparation of 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxyethyl]- 8-hydroxy-(1h)-quinolin-2-one (indacaterol)
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2015008229A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors
WO2015008230A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015104718A2 (en) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
WO2015145353A1 (en) 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
WO2015162558A1 (en) 2014-04-24 2015-10-29 Novartis Ag Autotaxin inhibitors
EP3138837A1 (en) 2012-09-21 2017-03-08 Crystal Pharma, S.A.U. Indacaterol free base in solid form
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
EP3205646A2 (en) 2013-03-27 2017-08-16 Laboratorios Lesvi, S.L. Intermediates for the manufacture of (r)-5-[2- (5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one (indacaterol)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693603B (en) * 2014-11-24 2019-11-29 上海医药工业研究院 The maleic acid datro preparation process of improvement
KR101769204B1 (en) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 New method for preparation of chiral chromanol derivatives
CN107394260B (en) * 2016-05-17 2020-06-09 财团法人工业技术研究院 Metal ion battery
CN107868045A (en) * 2016-09-28 2018-04-03 四川海思科制药有限公司 A kind of preparation method of QAB-149 intermediate
CN113731406B (en) * 2021-10-12 2023-07-28 南京工业大学 Method for improving palladium carbon activity hydrogenation removal protecting group

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750701A (en) * 1994-03-15 1998-05-12 Smithkline Beecham Plc Heterocyclic ethanolamine derivatives with β-adrenoreceptor agonistic activity
WO2000075114A1 (en) * 1999-06-04 2000-12-14 Novartis Ag Beta2-adrenoceptor agonists
WO2004076422A1 (en) * 2003-02-28 2004-09-10 Novartis Ag Process for preparing 5-‘(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20050211A1 (en) * 2003-04-02 2005-04-27 Novartis Ag PROCEDURE TO PREPARE OXY- (1H) -QUINOLIN-2-ONAS 5- (ALPHA-HALOACETIL) -8-SUBSTITUTED

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750701A (en) * 1994-03-15 1998-05-12 Smithkline Beecham Plc Heterocyclic ethanolamine derivatives with β-adrenoreceptor agonistic activity
WO2000075114A1 (en) * 1999-06-04 2000-12-14 Novartis Ag Beta2-adrenoceptor agonists
WO2004076422A1 (en) * 2003-02-28 2004-09-10 Novartis Ag Process for preparing 5-‘(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. PÜNTENER ET. AL.: "New Efficient Catalysts for Enantioselective Transfer Hydrogenations." TETRAHEDRON LETTERS, vol. 37, no. 45, 1996, pages 8165-8168, XP002367502 cited in the application *
KERL-JOSEF HAACK ET. AL.: "The Catalyst Precursor, Catalyst, and Intermediate in the Ru(II) Promoted Asymmetric Hydrogen Transfer Between Alcohols and Ketones." ANGEWANDTE CHEMIE, INTERNATIONAL EDITION IN ENGLISH, vol. 36, no. 3, 1997, pages 285-288, XP002367503 cited in the application *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
WO2008025816A1 (en) * 2006-08-31 2008-03-06 Novartis Ag Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
US9169277B2 (en) 2010-03-01 2015-10-27 Massachusetts Institute Of Technology Epoxidation catalysts
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
WO2012007539A1 (en) 2010-07-14 2012-01-19 Novartis Ag Ip receptor agonist heterocyclic compounds
WO2012106575A1 (en) 2011-02-04 2012-08-09 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105066A1 (en) 2012-01-13 2013-07-18 Novartis Ag Salts of an ip receptor agonist
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2014008640A1 (en) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 Indacaterol intermediate and method for synthesizing indacaterol
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP3848354A1 (en) 2012-09-21 2021-07-14 Crystal Pharma, S.A.U. Process for the preparation of indacaterol and intermediates thereof
EP3138837A1 (en) 2012-09-21 2017-03-08 Crystal Pharma, S.A.U. Indacaterol free base in solid form
WO2014097151A2 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
WO2014141135A1 (en) 2013-03-14 2014-09-18 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9744178B2 (en) 2013-03-14 2017-08-29 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014139485A1 (en) 2013-03-15 2014-09-18 Zentiva, K.S. A method for the preparation of 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-l-hydroxyethyl]- 8-hydroxy-(1h)-quinolin-2-one (indacaterol)
EP3205646A2 (en) 2013-03-27 2017-08-16 Laboratorios Lesvi, S.L. Intermediates for the manufacture of (r)-5-[2- (5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one (indacaterol)
WO2015008230A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015008229A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors
WO2015104718A2 (en) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
WO2015145353A1 (en) 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
WO2015162558A1 (en) 2014-04-24 2015-10-29 Novartis Ag Autotaxin inhibitors
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate

Also Published As

Publication number Publication date
PE20060304A1 (en) 2006-05-19
PL1791820T3 (en) 2010-05-31
AU2005254698B2 (en) 2008-09-25
TW200615265A (en) 2006-05-16
PT1791820E (en) 2010-02-23
IL179600A (en) 2011-11-30
SI1791820T1 (en) 2010-04-30
EP1791820B1 (en) 2009-12-02
GB0413960D0 (en) 2004-07-28
CN1968927B (en) 2010-07-21
HK1105121A1 (en) 2008-02-01
WO2005123684A3 (en) 2006-06-01
CN1968927A (en) 2007-05-23
US20120220775A1 (en) 2012-08-30
NO20070400L (en) 2007-03-21
TNSN06408A1 (en) 2008-02-22
ES2337273T3 (en) 2010-04-22
RU2007102228A (en) 2008-07-27
MY142051A (en) 2010-08-30
AR049553A1 (en) 2006-08-16
ECSP067100A (en) 2007-01-26
MA28687B1 (en) 2007-06-01
KR20070029752A (en) 2007-03-14
CA2566388A1 (en) 2005-12-29
RU2383534C2 (en) 2010-03-10
IL179600A0 (en) 2007-05-15
JP5064214B2 (en) 2012-10-31
CY1109884T1 (en) 2014-09-10
NZ551276A (en) 2010-06-25
ATE450512T1 (en) 2009-12-15
DE602005018076D1 (en) 2010-01-14
US20090054653A1 (en) 2009-02-26
CA2566388C (en) 2013-04-16
NO339079B1 (en) 2016-11-07
JP2008503526A (en) 2008-02-07
BRPI0512298A (en) 2008-03-25
HRP20100087T1 (en) 2010-06-30
AR082981A2 (en) 2013-01-23
KR101179302B1 (en) 2012-09-03
EP1791820A2 (en) 2007-06-06
DK1791820T3 (en) 2010-04-06
TWI347317B (en) 2011-08-21
MXPA06014695A (en) 2007-02-12
ZA200609257B (en) 2008-07-30
AU2005254698A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
EP1791820B1 (en) Enantioselective preparation of quinoline derivatives
CA2517033C (en) Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist
KR101073740B1 (en) 5--8- -1--2- a process for the preparation of 5-haloacetyl-8-substituted oxy-1h-quinolin-2-ones
WO2017208251A1 (en) A new stable polymorph of brexpiprazole and process for preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005770221

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6563/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/09257

Country of ref document: ZA

Ref document number: 12006502207

Country of ref document: PH

Ref document number: 200609257

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2566388

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 551276

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005254698

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014695

Country of ref document: MX

Ref document number: 200580019589.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007517180

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 06127752

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020067026958

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005254698

Country of ref document: AU

Date of ref document: 20050621

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005254698

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2007000039

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007102228

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020067026958

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005770221

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512298

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 11569140

Country of ref document: US